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Abstract Cytokines elicit pleiotropic and non-redundant activities despite strong overlap in their
usage of receptors, JAKs and STATs molecules. We use IL-6 and IL-27 to ask how two cytokines
activating the same signaling pathway have different biological roles. We found that IL-27 induces
more sustained STAT1 phosphorylation than IL-6, with the two cytokines inducing comparable
levels of STAT3 phosphorylation. Mathematical and statistical modeling of IL-6 and IL-27 signaling
identified STAT3 binding to GP130, and STAT1 binding to IL-27Ra, as the main dynamical
processes contributing to sustained pSTAT1 levels by IL-27. Mutation of Tyr613 on IL-27Ra
decreased IL-27-induced STAT1 phosphorylation by 80% but had limited effect on STAT3
phosphorgylation. Strong receptor/STAT coupling by IL-27 initiated a unique gene expression
program, which required sustained STAT1 phosphorylation and IRF1 expression and was enriched
in classical Interferon Stimulated Genes. Interestingly, the STAT/receptor coupling exhibited by IL-
6/IL-27 was altered in patients with systemic lupus erythematosus (SLE). IL-6/IL-27 induced a more
potent STAT1 activation in SLE patients than in healthy controls, which correlated with higher
STAT1 expression in these patients. Partial inhibition of JAK activation by sub-saturating doses of
Tofacitinib specifically lowered the levels of STAT1 activation by IL-6. Our data show that receptor
and STATs concentrations critically contribute to shape cytokine responses and generate functional
pleiotropy in health and disease.
Introduction
IL-27 and IL-6 both have intricate functions regulating inflammatory responses (O’Shea and Plenge,
2012). IL-27 is a hetero-dimeric cytokine comprised of p28 and EBI3 subunits (Pflanz et al., 2002).
IL-27 exerts its activities by binding GP130 and IL-27Ra receptor subunits in the surface of respon-
sive cells, triggering the activation of the JAK1/STAT1/STAT3 signaling pathway. IL-27 elicits both
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pro- and anti-inflammatory responses, although the later activity seems to be the dominant one
(Yoshida and Hunter, 2015). IL-27 stimulation inhibits RORgt expression, thereby suppressing Th-17
commitment and limiting subsequent production of pro-inflammatory IL-17 (Stumhofer et al., 2006;
Diveu et al., 2009). Moreover, IL-27 induces a strong production of anti-inflammatory IL-10 on
(Tbet+ and FoxP3-) Tr-1 cells (Fitzgerald et al., 2007; Stumhofer et al., 2007; Pot et al., 2011) fur-
ther contributing to limit the inflammatory response. IL-6 engages a hexameric receptor complex
comprised each of two copies of IL-6Ra, GP130 and IL-6 (Boulanger et al., 2003), triggering the
activation, as IL-27 does, of the JAK1/STAT1/STAT3 signaling pathway. However, opposite to IL-27,
IL-6 is known as a paradigm pro-inflammatory cytokine (Rose-John, 2018; Hunter and Jones,
2015). IL-6 inhibits lineage differentiation to Treg cells (Korn et al., 2008) while promoting that of
Th-17 cells (Kimura and Kishimoto, 2010; Jones et al., 2010), thus supporting its pro-inflammatory
role. How IL-27 and IL-6 elicit opposite immunomodulatory activities despite activating almost identi-
cal signaling pathways is currently not completely understood.
The relative and absolute STAT activation levels seem to have a diverse set of roles, which lead to
a strong signaling and functional plasticity by cytokines. Although IL-6 robustly activates STAT3, it is
capable to mount a considerable STAT1 response as well (Rolvering et al., 2017). Moreover, in the
absence of STAT3, IL-6 induces a strong STAT1 response comparable to IFNg – a prototypic STAT1
activating cytokine (Costa-Pereira et al., 2002). Likewise, the absence of STAT1 potentiates the
STAT3 response for IL-27, which normally elicits a strong STAT1 response, rendering it to mount an
IL-6-like response (Rolvering et al., 2017). This suggests a competition of STAT1/3 for phospho-
tyrosine motifs at the cytoplasmic domain of cytokine receptors regulated by their different binding
rate constants (on and off rates). Indeed, different STAT1 or STAT3 binding affinities have been
assessed in vitro for the phospho-tyrosines on GP130 (Wiederkehr-Adam et al., 2003). Further-
more, negative feedback mechanisms, controlled by SOCSs and phosphatases, have been described
as critical players influencing STAT1 and STAT3 phosphorylation kinetics and thereby shaping their
signal integration for GP130-utilizing cytokines (Schmitz et al., 2000; Yasukawa et al., 2003;
Croker et al., 2003; Brender et al., 2007). Yet, how all these molecular components are integrated
by a given cell to produce the desired response is still an open question. Among the IL-6/IL-12 cyto-
kine family, IL-27 exhibits a unique STAT activation pattern. The majority of GP130-engaging cyto-
kines activate preferentially STAT3, with activation of STAT1 an accessory or balancing component
in the signaling pathway (Camporeale, 2012; Regis et al., 2008). IL-27, however, triggers STAT1
and STAT3 activation with high potency (Lucas et al., 2003). Indeed, different studies have shown
that IL-27 responses rely on either STAT1 (Kamiya et al., 2004; Takeda et al., 2003; Neufert et al.,
2007) or STAT3 activation (Stumhofer et al., 2007; Owaki et al., 2008). Moreover, recent transcrip-
tomics studies showed that in the absence of STAT3, IL-6 and IL-27 lost more than 75% of target
gene induction. Yet, STAT1 was the main factor driving the specificity of the IL-27 versus the IL-6
response, highlighting a critical interplay of STAT1 and STAT3 engagement (Hirahara et al., 2015).
While the biological responses induced by IL-27 and IL-6 have been extensively studied
(Yoshida and Hunter, 2015; Hunter and Jones, 2015), the very initial steps of signal activation and
kinetic integration by these two cytokines have not been comprehensively analysed. Since the differ-
ent biological outcomes elicited by IL-27 and IL-6 are most likely encoded in the early events of cyto-
kine stimulation, here we specifically aimed to identify the molecular determinants underlying
functional selectivity by IL-27 in human T-cells. We asked how a defined cytokine stimulus is propa-
gated in time over multiple layers of signaling to produce the desired response. To this end, we
probed IL-27 and IL-6 signaling at different scales, ranging from cell surface receptor assembly and
early STAT1/3 effector activation to an unbiased and quantitative multi-omics approach: phospho-
proteomics after early cytokine stimulation, kinetics of transcriptomic changes and alteration of the
T-cell proteome upon prolonged cytokine exposure.
IL-6 and IL-27 induced similar levels of assembly of their respective receptor complexes, which
resulted in comparable phosphorylation of STAT3 by the two cytokines. IL-27, on the other hand,
triggered a more sustained STAT1 phosphorylation. To decipher the molecular events which deter-
mine sustained STAT1 phosphorylation by IL-27, we mathematically model the STAT1 and STAT3
signaling kinetics induced by each of these cytokines. We identified differential binding of STAT1
and STAT3 to IL-27Ra and GP130, respectively, as the main factors contributing to a sustained
STAT1 activation by IL-27. At the transcriptional level, IL-27 triggered the expression of a unique
gene program, which strictly required the cooperative action between sustained pSTAT1 and IRF1
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expression to drive the induction of an interferon-like gene signature that profoundly shaped the
T-cell proteome. Interestingly, our mathematical models of IL-6 and IL-27 signaling predicted that
changes in receptor and STAT expression could fundamentally change the magnitude and timescale
of the IL-6 and IL-27 responses. We found high levels of STAT1 expression in SLE patients when
compared to healthy donors, which correlated with biased STAT1 responses induced by IL-6 and IL-
27 in these patients. Strikingly, we could specifically inhibit STAT1 activation by IL-6 using subopti-
mal doses of the JAK inhibitor Tofacitinib. This could provide a new strategy to specifically target
individual STATs engaged by cytokines.
Results
IL-27 induces a more sustained STAT1 activation than HypIL-6 in human
Th-1 cells
IL-6 and IL-27 are critical immunomodulatory cytokines. Although IL-6 engages a hexameric surface
receptor comprised of two molecules of IL-6Ra and two molecules of GP130 to trigger the activation
of STAT1 and STAT3 transcription factors (Figure 1a), IL-27 binds GP130 and IL-27Ra to trigger acti-
vation of the same STATs molecules (Figure 1a). Despite sharing a common receptor subunit,
GP130, and activating similar signaling pathways, these two cytokines exhibit non-redundant immu-
nomodulatory activities, with IL-6 eliciting a potent pro-inflammatory response and IL-27 acting
more as an anti-inflammatory cytokine. Here, we set to investigate the molecular rules that deter-
mine the functional specificity elicited by IL-6 and IL-27 using human Th-1 cells as a model experi-
mental system. Due to the challenging recombinant expression of the human IL-27, we have
recombinantly produced a murine single-chain variant of IL-27 (p28 and EBI3) which cross-reacts with
the human receptors and triggers potent signaling, comparable to the signaling output produced by
commercial human IL-27 (Oniki et al., 2006; Figure 1—figure supplement 1a). In addition, we have
used a linker-connected single-chain fusion protein of IL-6Ra and IL-6 termed HyperIL-6 (HypIL-6)
(Fischer et al., 1997) to diminish IL-6 signaling variability due to changes in IL-6Ra expression during
T cell activation (Oberg et al., 2006).
CD4 +T cells from human buffy coat samples were isolated by magnetic activated cell sorting
(MACS) and grew under Th-1-polarizing conditions. Th-1 cells were then used to study in vitro signal-
ing by IL-27 and IL-6 (Figure 1—figure supplement 1b). We took advantage of a barcoding meth-
odology allowing high-throughput multiparameter flow cytometry to perform detailed dose/
response and kinetics studies induced by HypIL-6 and IL-27 in Th-1 cells (Krutzik et al., 2011; Fig-
ure 1—figure supplement 1b). Dose-response experiments with IL-27 and HypIL-6 on Th-1 cells
showed concentration-dependent phosphorylation of STAT1 and STAT3. Phosphorylation of STAT1/
3 was more sensitive to activation by IL-27 with an EC50 of ~20 pM compared to ~400 pM for HypIL-
6 (Figure 1b). Despite this difference in sensitivity, both cytokines yielded the same activation ampli-
tude for pSTAT3. For pSTAT1, however, we observed a significantly reduced maximal amplitude for
HypIL-6 relative to IL-27 (Figure 1b). We next performed kinetic studies to assess whether the poor
STAT1 activation by HypIL-6 was a result from different activation kinetics. For STAT3, we saw the
peak of phosphorylation after ~15–30 min, followed by a gradual decline. Both cytokines exhibited
an almost identical sustained pSTAT3 profile, with ~20% of activation still seen after 3 hr of continu-
ous stimulation. Interestingly, IL-27 did not only activate STAT1 with higher amplitude but also more
sustained than HypIL-6 (Figure 1c). This could be better appreciated when pSTAT1 levels were nor-
malized to maximal MFI for each cytokine, with IL-27 inducing clearly a more sustain phosphorylation
of STAT1 than HypIL-6 (Figure 1—figure supplement 1c). The same phenotype was observed in
other T-cell subsets of activated PBMCs (Figure 1—figure supplement 1d). As cell surface GP130
levels are significantly reduced upon T-cell activation (Betz and Müller, 1998), we next investigated
whether the transient STAT1 activation profile induced by HypIL-6 resulted from limited availability
of GP130. For that we generated a RPE1 cell clone stably expressing 10 times higher levels of
GP130 in its surface (Figure 1d, right panel). Stimulation of this RPE1 clone with HypIL-6 resulted in
a more sustained activation of STAT3, with very little effect on STAT1 activation kinetics when com-
pared to RPE1 wild-type cells, suggesting that GP130 receptor density does not contribute to the
transient STAT1 activation kinetics elicited by HypIL-6 (Figure 1d).
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Figure 1. Cytokine receptor activation by IL-27 and (Hyp)IL-6: (a) Cartoon model of stepwise assembly of the IL-27 and HypIL-6-induced receptor
complex and subsequent activation of STAT1 and STAT3. (b) Dose-dependent phosphorylation of STAT1 and STAT3 as a response to IL-27 and HypIL-
6 stimulation in TH-1 cells, normalized to maximal IL-27 stimulation. Data was obtained from three biological replicates with each two technical
replicates, showing mean ±std dev. (c) Phosphorylation kinetics of STAT1 and STAT3 followed after stimulation with saturating concentrations of IL-27 (2
Figure 1 continued on next page
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Ligand-induced cell-surface receptor assembly by IL-27 and HypIL-6
We next investigated whether IL-27 and HypIL-6 elicited differential cell surface receptor engage-
ment that could explain their distinct signaling output. For that, we measured the dynamics of recep-
tor assembly in the plasma membrane of live cells by simultaneous dual-color total internal reflection
fluorescence (TIRF) imaging. RPE1 cells were chosen as a model experimental system since they do
not express endogenous IL-27Ra (Figure 1—figure supplement 2a). We generated an RPE1 clone,
stably expressing IL-27Ra which responds to IL-27 and HypIL-6 stimulation. Importantly, this recon-
stituted experimental system mimicked the pSTAT1/3 activation kinetics of T-cells (Supp. Fig. 2b),
albeit exhibiting similar pSTAT1 amplitudes for IL-27 and HypIL-6, most likely because of the high
endogenous levels of GP130 in RPE1 cells. We used previously described RPE1 GP130 KO cells (Fig-
ure 1—figure supplement 2; Martinez-
Fabregas et al., 2019) to transfect and express
tagged variants of IL-27Ra and GP130, to allow
quantitative site-specific fluorescence cell surface
labeling by dye-conjugated nanobodies (NBs)
Figure 1 continued
nM) and HypIL-6 (20 nM) or unstimulated TH-1 cells, normalized to maximal IL-27 stimulation. Data was obtained from five biological replicates with
each two technical replicates, showing mean ±std dev. (d) Top: Phosphorylation kinetics of STAT1 and STAT3 followed after stimulation with HypIL-6 (20
nM) or left unstimulated, comparing wt RPE1 and RPE1 GP130KO reconstituted with high levels of mXFPm-GP130 (=10 x [GP130]). Data was normalized
to maximal stimulation levels of each treatment. Left: cell surface GP130 levels comparing RPE1 GP130KO, wt RPE1 and RPE1 GP130KO stably
expressing mXFPm-GP130 measured by flow cytometry. Data was obtained from one biological replicate with each two technical replicates, showing
mean ±std dev. Bottom right: cell surface levels of GP130 measured by flow cytometry for indicated cell lines. (e) Cartoon model of cell surface labeling
of mXFP-tagged receptors by dye-conjugated anti-GFP nanobodies (NB) and identification of receptor dimers by single molecule dual-color co-
localization. (f) Raw data of dual-color single-molecule TIRF imaging of mXFPe-IL-27RaNB-RHO11 and GP130NB-DY649 after stimulation with IL-27. Particles
from the insets (IL-27Ra: red and GP130: blue) were followed by single molecule tracking (150 frames ~ 4.8 s) and trajectories > 10 steps (320 ms) are
displayed. Receptor heterodimerization was detected by co-localization/co-tracking analysis. (g) Relative number of co-trajectories observed for
heterodimerization of IL-27Ra and GP130 as well as homodimerization of GP130 for unstimulated cells or after indicated cytokine stimulation. Each data
point represents the analysis from one cell with a minimum of 23 cells measured for each condition. Two-tailed Student’s T-test: *p<0.05, **p0.01,
***p0.001; n.s., not significant. (h) Stoichiometry of the IL-27–induced receptor complex revealed by bleaching analysis. Left: Intensity traces of
mXFPe-IL-27RaNB-RHO11 and GP130NB-DY649 were followed until fluorophore bleaching. Middle: Merged imaging raw data for selected timepoints.
Right: overlay of the trajectories for IL-27Ra (red) and GP130 (blue).
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Characterization of IL-27 and HypIL-6 signaling in T-cell subsets followed by high-throughput flow-cytometry.
Figure supplement 2. Functional characterization of RPE1 IL-27Ra.
Figure supplement 3. Ligand-induced receptor assembly - stoichiometry and diffusion properties.
Video 1. Single-molecule co-tracking as a readout for
dimerization of cytokine receptors. Cell surface labeling
of mXFPe-IL-27Ra by eNBRHO11 (left, top) and mXFPm-
GP130 by mNBDY649 (left, bottom) after stimulation with
IL-27 (20 nM). In the overlay of the zoomed section of
both spectral channels (mXFPe-IL-27RaRHO11: Red,
mXFPm-GP130DY649: Blue), yellow lines indicate co-
locomotion of IL-27Ra and GP130 (10 steps).
Acquisition frame rate: 30 Hz, Playback: real time.
https://elifesciences.org/articles/66014#video1
Video 2. Dynamics of IL-27-induced receptor assembly.
Formation of a single-molecule heterodimer of mXFPe-
IL-27RaRHO11 (Red) and mXFPm-GP130DY649 (Blue) in
presence of IL-27. Yellow lines indicate co-locomotion
of IL-27Ra and GP130 (10 steps). Acquisition frame
rate: 30 Hz, Playback: real time with break at time of
receptor dimerization.
https://elifesciences.org/articles/66014#video2
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(Figure 1e) as recently described in Gorby et al., 2020. For both IL-27Ra and GP130, we found a
random distribution and unhindered lateral diffusion of individual receptor monomers (Figure 1f).
Single-molecule co-localization combined with co-tracking analysis was then used to identify corre-
lated motion of IL-27Ra and GP130 which was taken as a readout for receptor heterodimer forma-
tion (Ruprecht et al., 2010; Figure 1f, Video 1). In the resting state, we did not observe pre-
assembly of IL-27Ra and GP130. However, after stimulation with IL-27 we found substantial hetero-
dimerization (Figure 1f and g, Figure 1—figure supplement 3a, Video 1 and 2). At elevated laser
intensities, bleaching analysis of individual complexes confirmed a one-to-one (1:1) complex stoichi-
ometry of IL-27Ra and GP130, whereas single-molecule Förster resonance energy transfer (FRET)
further corroborated close molecular proximity of the two receptor chains (Figure 1h). We also
observed association and dissociation events of receptor heterodimers, pointing to a dynamic equi-
librium between monomers and dimers as proposed for other heterodimeric cytokine receptor sys-
tems (Moraga et al., 2015a; Wilmes et al., 2015; Video 3).
To measure homodimerization of GP130 by HypIL-6, we stochastically labeled GP130 with equal
concentrations of the same NB species conjugated to either of the two dyes (Wilmes et al., 2020).
We saw strong homodimerization of GP130 after stimulation with HypIL-6 (Figure 1g, Figure 1—fig-
ure supplement 3a, Video 4). Homodimerization was confirmed either by single-color dual-step
bleaching or dual-color single-step bleaching as shown for other homodimeric cytokine receptors
(Figure 1—figure supplement 3b; Pflanz et al., 2004). For both cytokine receptor systems, we saw
a cytokine-induced reduction of the diffusion mobility, which has been ascribed to increased friction
of receptor dimers diffusing in the plasma membrane. However, we note that HypIL-6 stimulation
impaired diffusion of GP130 more strongly than IL-27 did, possibly indicating faster receptor inter-
nalization (Figure 1—figure supplement 3c). Based on the dimerization data, we were able to calcu-
late the two-dimensional equilibrium dissociation constants (K2DD ) assuming mass action kinetics for a
dynamic monomer-dimer equilibrium: for IL-27-induced heterodimerization of IL-27Ra and GP130,
we calculated a two-dimensional constant, denoted by K2DD ; of approximately 0.81 mm
 2. In activated
T-cells with high levels and a significant excess of IL-27Ra over GP130, this K2DD ensures strong
receptor assembly by IL-27 (Diegelmann et al., 2012). K2DD for GP130 homodimerization by HypIL-6
was approximately 0.21 mm 2. This higher affinity is most likely due to the two high-affinity binding
sites engaged in the hexameric receptor complex (Boulanger et al., 2003). However, in T-cells the
expression of GP130 can be particularly low, thus, probably limiting HypIL-6-induced signaling.
Taken together, these experiments marked ligand-induced receptor assembly as the initial step trig-
gering downstream signaling for both IL-27 and HypIL-6, with no obvious differences in their recep-
tor activation mechanism which could support the observed more sustained STAT1 activation
elicited by IL-27.
Mathematical and statistical
analysis of HypIL-6 and IL-27-
induced STAT kinetic responses
To gain further insight into the molecular rules
and kinetics that define IL-27 sustained STAT1
phosphorylation, we developed two mathemati-
cal models of the initial steps of HypIL-6 and IL-
27 receptor-mediated signaling, respectively. A
diagram which describes the molecular reactions
in each model is shown in Figure 2—figure sup-
plement 1a, and the complete model reaction
scheme is given in Figure 2—figure supplement
1b–h. The mathematical model for each cytokine
considers the following events: (i) cytokine asso-
ciation and dissociation to a receptor chain
(Figure 2a, Figure 2—figure supplement 1b
and c, top panel), (ii) cytokine-induced dimer
association and dissociation (Figure 2—figure
supplement 1b and c, bottom panel), (iii) STAT1
Video 3. Ligand-induced heterodimerization of IL-27Ra
and GP130. Overlay of the two spectral channels
(mXFPe-IL-27RaRHO11: Red, mXFPm-GP130DY649: Blue)
in absence (left) or presence (right) of IL-27 (20 nM).
Yellow lines indicate co-locomotion of IL-27Ra and
GP130 (10 steps). Acquisition frame rate: 30 Hz,
Playback: real time.
https://elifesciences.org/articles/66014#video3
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(or STAT3) binding and unbinding to dimer (Figure 2—figure supplement 1d and e), (iv) STAT1 (or
STAT3) phosphorylation when bound to dimer (Figure 2—figure supplement 1d and e), (v) internal-
ization/degradation of complexes (Figure 2—figure supplement 1f and g), and (vi) dephosphoryla-
tion of free STAT1 (or STAT3) (Figure 2—figure supplement 1h). Details of model assumptions,
model parameters and parameter inference have been provided in the Materials and methods under
the sections Mathematical models and Bayesian inference. The ordinary differential equations for
each mathematical model are given in Supplementary Information 1, where we have assumed mass
action kinetics.
We first wanted to explore if there existed a potential feedback mechanism in the mechanisms of
receptor complexes internalization/degradation over time. Negative feedback mechanisms have
been reported for cytokine receptor signaling, while positive feedback loops are unlikely to happen
at the timescale of the given experiments (3 hr). To this end, and for each cytokine model, we con-
sidered two hypotheses: hypothesis one assumes that receptor complexes (Figure 2—figure supple-
ment 1f and g) are internalized with rate proportional to the concentration of the species in which
they are contained (e.g. different dimer types), and hypothesis 2, that receptor complexes are inter-
nalized with rate proportional to the product of the concentration of the species in which they are
contained and the sum of the concentrations of free cytoplasmic phosphorylated STAT1 and STAT3.
Hypothesis 2 is consistent with a negative feedback mechanism in which pSTAT molecules translo-
cate to the nucleus, where they increase the translation of negative feedback proteins such as
SOCS3. In order not to increase the complexity of the mathematical models with additional variables
and parameters, we chose to include the feedback mechanism in hypothesis two implicitly, rather
than by considering new equations for species such as SOCS3. Details of the two model hypotheses
are described in the Materials and methods (Mathematical models).
We first carried out a structural identifiability analysis (Castro and de Boer, 2020) for the IL-27
and HypIL-6 mathematical models under both hypotheses, to determine which of the model parame-
ters could be independently inferred. We found that all model parameters and initial concentrations
were structurally identifiable, given the data and the known experimental initial concentrations. We
made use of the RPE1 experimental data set to carry out Bayesian model selection for the two differ-
ent hypotheses. We found that hypothesis 1 could explain the data better than hypothesis 2, with a
probability of 99%. This result can be seen in Figure 2b, in which we plot, for different values of the
distance threshold, d, between the mathematical model output and the data (see Mathematical
models and Bayesian inference in Materials and methods, for details), the relative probability of each
hypothesis, where hypothesis 1 is denoted H1 and hypothesis 2 is denoted H2. It can be observed
that for smaller values of the distance threshold, which indicate data and mathematical model results
are closer, the relative probability of hypothesis 1 is higher than that of hypothesis 2.
We then made use of this result to explore the mathematical models for both cytokines under
hypothesis 1, in particular we performed parameter calibration. To this end (and as described in
Materials and methods under Mathematical models and Bayesian inference), we carried out Bayesian
inference (ABC-SMC Toni et al., 2009) together with the mathematical models (hypothesis 1) and
the experimental data sets to quantify the reaction rates (Figure 2—figure supplement 1) and initial
molecular concentrations (see Table 2 and Table 3). The Bayesian parameter calibration of the two
models of cytokine signaling allows one to quantify the observed kinetics of pSTAT1/3 phosphoryla-
tion induced by HypIL-6 and IL-27 in RPE1 and Th-1 cells (Figure 2c). Substantial differences in STAT
association rates to and dissociation rates from the dimeric complexes were inferred to critically con-
tribute to defining pSTAT1/3 kinetics. Figure 2d shows the kernel density estimates (KDEs) for the
posterior distributions of the rate constants and initial concentrations in the models. kþia denotes the
rate at which STATi binds to GP130 and kþib denotes the rate at which STATi binds to IL-27Ra,
for i 2 1; 3f g. Our results indicate that STAT1 and STAT3 exhibit different binding preferences




STAT3 exhibits stronger binding to GP130 than IL-27Ra, (kþ
3a>k
þ
3b) in agreement with previous obser-
vations (17). To further quantify these differences in the posterior distributions for the STAT binding
rates, Table 1 provides summary statistics for each of these rates. For example, from the table we
see that there is a difference of at least one order of magnitude between the means and medians of
the pairs of STAT/receptor binding parameters (kþia compared with k
þ
ib for i 2 1; 3f g). Finally, we note
that, although there exist some significant correlations between posterior distributions for pairs of
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parameters in the analysis, for all four pairs of
STAT/receptor interaction parameters (second
row of Figure 2d), the absolute value of the cor-
relation coefficient is less than 0.25, and thus, the
posterior distributions are representative of the
rates they correspond to.
IL-27Ra cytoplasmic domain is
required for sustained pSTAT1
kinetics
The Bayesian inference carried out with the
experimental data and the mathematical models
clearly indicated statistically significant differen-
ces in the binding rates of STAT1/STAT3 to
GP130 and IL-27Ra, to account for the different
phosphorylation kinetics exhibited by HypIL-6
and IL-27. Thus, we next investigated whether
the more sustained STAT1 activation by IL-27
resulted from its specific engagement of IL-27Ra.
For that, we used RPE1 cells, which do not
express IL-27Ra (Figure 1—figure supplement
2a), to systematically dissect the contribution of
the IL-27Ra cytoplasmic domain to the differential pSTAT activation by IL-27. IL-27Ra’s intracellular
domain is very short and only encodes two Tyr susceptible to be phosphorylated in response to IL-
27 stimulation, that is, Tyr543 and Ty613 (Figure 3a). We mutated these two Tyr to Phe to analyse
their contribution to IL-27 induced signaling. We stably expressed WT IL-27Ra as well as different IL-
27Ra Tyr mutants in RPE1 cells with comparable cell surface expression levels (Figure 3b). As the
endogenous GP130 expression levels remain unaltered, all generated clones exhibited very compa-
rable responses to HypIL-6 (Figure 3b, bottom panels). IL-27 triggered comparable levels of STAT1
and STAT3 activation in RPE1 cells reconstituted with IL-27Ra WT and IL-27Ra Y543F mutant, sug-
gesting that this Tyr residue does not contribute to signaling by this cytokine (Figure 3b and Fig-
ure 3—figure supplement 1a). In RPE1 cells reconstituted with the IL-27Ra Y613F or Y543F-Y613F
mutants, IL-27 stimulation resulted in 80% of the STAT3 activation, but only 20% of the STAT1 acti-
vation levels induced by this cytokine relative to IL-27Ra WT (Figure 3b; Pradhan et al., 2010).
These observations suggest a tight coupling of STAT phosphorylation to one of the receptor chains;
namely, IL-27Ra with pSTAT1 and GP130 with pSTAT3, respectively. We next tested how the cyto-
plasmic domains of GP130 and IL-27Ra shape the pSTAT kinetic profiles. Thus, we generated a sta-
ble RPE1 clone expressing a chimeric construct comprised of the extracellular and transmembrane
domain of IL-27Ra but the cytoplasmic domain of GP130 (Figure 3c, Figure 3—figure supplement
1b). Again, as both cell lines express unaltered endogenous GP130 levels, they exhibited compara-
ble responses to HyIL-6 (Figure 3c). Strikingly, this domain-swap resulted in a transient pSTAT1
kinetic response by IL-27 comparable to HypIL-6 stimulation. STAT3 activation on the other hand
remained unaltered suggesting that the cytoplasmic domain of IL-27Ra is essential for a sustained
pSTAT1 response but not for pSTAT3.
Two plausible scenarios could explain the observed pSTAT1/3 activation differential by HypIL-6
and IL-27: (i) IL-27Ra-JAK2 complex phosphorylates STAT1 faster than GP130-JAK1 complex or (ii)
pSTAT1 is more quickly dephosphorylated in the IL-6/GP130 receptor homodimer. In the latter case,
pSTAT deactivation by constitutively expressed phosphatases could be an additional factor of regu-
lation. Indeed, SHP-2 has been described to bind to GP130 and shape IL-6 responses (Kim et al.,
1998). However, our Bayesian inference results (together with the mathematical models and the
experimental data) identified the STAT/receptor association rates as the only rates that could
account for the greater and more sustained activation of STAT1 by IL-27. We note (as described in
the Materials and methods) that the phosphorylation rate, denoted by q, of STAT1 and STAT3 when
bound to a dimer (homo- or hetero-) has been assumed to be independent of the STAT type and
the receptor chain. Moreover, the model also included dephosphorylation of free pSTAT molecules,
and predicted that the rates at which these reactions occur (d1 and d3) had rather similar posterior
Video 4. Ligand-induced homodimerization of GP130.
Overlay of the two spectral channels (mXFPm-
GP130RHO11: Red, mXFPm-GP130DY649: Blue) in
absence (left) or presence (right) of HypIL-6 (20 nM).
Yellow lines indicate co-locomotion of IL-27Ra and
GP130 (10 steps). Acquisition frame rate: 30 Hz,
Playback: real time.
https://elifesciences.org/articles/66014#video4
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Figure 2. Mathematical modeling results in RPE1 and Th-1 cells. (a) Simplified cartoon model of IL-27/HypIL-6 signal propagation layers and coverage
of the mathematical modeling approach. (b) Model selection results showing the relative probabilities of each hypothesis, for different values of the
distance threshold, d, in RPE1 cells. (c) Pointwise median and 95% credible intervals of the predictions from the mathematical model, calibrated with
the experimental data, using the posterior distributions for the parameters from the ABC-SMC. For the experimental data, phosphorylation kinetics of
Figure 2 continued on next page
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distributions, hence arguing against the potential role of phosphatases to specifically target STAT1
upon HypIL-6 stimulation. To distinguish between the two plausible scenarios, we next determined
the rates of pSTAT1/3 dephosphorylation by blocking JAK activity upon cytokine stimulation making
use of the JAK inhibitor Tofacitinib in RPE1 cells. Tofacitinib was added 15 min after stimulation with
either cytokine and pSTAT1 and pSTAT3 levels were measured at the indicated times. JAK inhibition
markedly shortened the pSTAT1/3 activation profiles induced by both cytokines (Figure 3d, Fig-
ure 3—figure supplement 1c). The relative dephosphorylation rates could then be determined by
the signal intensity ratio of +/- Tofacitinib. Even though pSTAT1 levels were more affected by JAK
inhibition than those of pSTAT3, the observed relative changes were nearly identical for IL-27 and
HypIL-6. These findings were also confirmed for Th-1 cells (Figure 3—figure supplement 1d and e)
and indicate, that selective phosphatase activity cannot serve as an explanation for the pSTAT1/3
differential by HypIL-6 and IL-27, in agreement with our mathematical modeling predictions. Simi-
larly, we tested whether neosynthesis of feedback inhibitors such as SOCS3 (Croker et al., 2003)
would selectively impair signaling by HypIL-6 but not by IL-27. To this end we pre-treated cells with
Cycloheximide (CHX) and followed the pSTAT1/3 kinetics induced by the two cytokines (Figure 3—
figure supplement 2a and b). CHX treatment resulted in more sustained pSTAT3 activity for both
cytokines. To our surprise, STAT1 phosphorylation by IL-27 was even more sustained while pSTAT1
levels induced by IL-6 remained unaffected. These observations exclude that feedback inhibitors
selectively impair STAT1 activation kinetics by HypIL-6 and thus do not account for the faster STAT1
dephosphorylation kinetics observed under HypIL-6 stimulation. Overall, our data from the chimera
and mutant experiments, which were not used in the Bayesian parameter calibration, provide addi-
tional support: they validate the mathematical models of HypIL-6 and IL-27 signaling and point to
the differential association/dissociation of STAT1 and STAT3 to IL-27Ra and GP130, respectively, as
the main factor defining STAT phosphorylation kinetics in response to HypIL-6 and IL-27 stimulation.
Unique and overlapping effects of IL-27 and HypIL-6 on the Th-1
phosphoproteome
Thus far, we have investigated the differential activation of STAT1/STAT3 induced by HypIL-6 and IL-
27. Next, we asked whether IL-27 and IL-6 induced the activation of additional and specific
Figure 2 continued
pSTAT1 and pSTAT3 were followed in RPE1 IL-27Ra after stimulation with saturating concentrations of IL-27 (2 nM) and HypIL-6 (10 nM). (d) Kernel
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mathematical models where j 2 6; 27f g and i 2 1; 3f g. A ’+’ in the parameter notation indicates that this is a forward rate constant (binding) and a ’–’ in
the notation indicates that this is a reverse rate constant (dissociation). In the first row, a ’6’ in the notation indicates that this is a reaction rate in the
HypIL-6 system and a ’27’ indicates that this is a reaction rate in the IL-27 system.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Schematic model of involved reactions and parameters for IL-27 and HypIL-6 receptor activation.
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Figure 3. IL-27Ra cytoplasmic domain is required for sustained pSTAT1 kinetics. (a) Representation of the cytoplasmic domain of IL-27Ra with its
highlighted tyrosine residues Y543 and Y613. (b) STAT1 and STAT3 phosphorylation kinetics of RPE1 clones stably expressing wt and mutant IL-27Ra
after stimulation with IL-27 (10 nM, top panels) or after stimulation with HypIL-6 (20 nM, bottom panels), normalized to maximal levels of wt IL-27Ra
stimulated with IL-27 (top) or HypIL-6 (bottom). Data was obtained from three experiments with each two technical replicates, showing mean ± std dev.
Figure 3 continued on next page
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intracellular signaling programs that could contribute to their unique biological profiles. To this end,
we investigated the IL-27 and HypIL-6 activated signalosome using quantitative mass-spectrometry-
based phospho-proteomics. MACS-isolated CD4+ were polarized into Th-1 cells and expanded in
vitro for stable isotope labeling by amino acids in cell culture (SILAC). Cells were then stimulated for
15 min with saturating concentrations of IL-27 (10 nM), HypIL-6 (20 nM) or left untreated. Samples
were enriched for phosphopeptides (Ti-IMAC), subjected to mass spectrometry and raw files ana-
lysed by MaxQuant software (Figure 4—figure supplement 1). In total we could quantify ~6400
phosphopeptides from 2600 proteins, identified across all conditions (unstimulated, IL-27, HypIL-6)
for at least two out of three tested donors. For IL-27 and HypIL-6 we detected similar numbers of
significantly upregulated (87 vs. 78) and downregulated (155 vs. 140) phosphorylation events
(Figure 4a) and systematically categorized them in context with their cellular location and ascribed
biological functions (Figure 4—figure supplement 1b and c; Huang et al., 2009b). The two cyto-
kines shared approximately half of the upregulated and one third of the downregulated phospho-
peptides (Figure 4—figure supplement 2a) but also exhibited differential target phosphorylation
(Figure 4b and Figure 4—figure supplement 2b). As expected, we found multiple members of the
STAT protein family among the top phosphorylation hits by the two cytokines, validating our study
(Figure 4b and c). In line with our previous observations, we detected the same relative amplitudes
for tyrosine phosphorylated STAT3 and STAT1. In addition to tyrosine-phosphorylation, we detected
robust serine-phosphorylation on S727 for STAT1 and STAT3 (Figure 4c). While pS-STAT1 activity
correlated with pY-STAT1 with IL-27 being more potent than HypIL-6, this was not the case for
STAT3. Despite an identical pY-STAT3 phosphorylation profile, HypIL-6 induced a ~50% higher pS-
STAT3 relative to IL-27 (Figure 4c). These results were corroborated, following the phosphorylation
kinetics of pS-STAT1 and pS-STAT3 by flow-cytometry (Figure 4d). Interestingly, while IL-27 and IL-6
have been described to also activate other signaling pathways, such as MAPK, p38, and AKT
(Diegelmann et al., 2012), we did not observe this in our phospho-target screening.
Given the overlapping phospho-proteomic changes, gene ontology (GO) analysis associated sev-
eral sets of phosphopeptides with biological processes that were mostly shared between both cyto-
kines (Figure 4e, Figure 4—figure supplement 2c). A large set of phospho-peptides was linked to
transcription initiation (including JAK/STAT signaling) or mRNA modification (Figure 4e). Interest-
ingly, IL-27 stimulation was associated to negative regulation of RNA polymerase II, whereas a posi-
tive regulation was detected for HypIL-6. A closer look into the functional regulation of RNA-pol II
activity by the two cytokines revealed that multiple proteins involved in this process were differen-
tially regulated by HypIL-6 and IL-27 (Figure 4f). While positive regulators of RNA-pol II transcrip-
tion, such as Negative Elongation Factor A (NELFA), PPM1G, RCHY1 and POL2RA, were much more
phosphorylated in response to HypIL-6 than IL-27, negative regulators of RNA-pol II transcription,
such as LARP7, were much more engaged by IL-27 treatment than by HypIL-6 (Figure 4f). Interest-
ingly, in a previous study we linked RNA-pol II regulation with the levels of STAT3 S727phosphoryla-
tion induced by HypIL-6 via recruitment of CDK8 to STAT3-dependent genes (Bancerek et al.,
2013). Our phospho-proteomic analysis thus, suggests that IL-27 and HypIL-6 recruit different tran-
scriptional complexes that ultimately could contribute to provide gene expression specificity by the
two cytokines. Additionally, we identified several interesting IL-27-specific phosphorylation targets.
One example was Ubiquitin Protein Ligase E3 Component N-Recognin 5 (UBR5). Phosphorylated
Figure 3 continued
Bottom right: cell surface levels variants measured by flow cytometry for indicated IL-27Ra cell lines. (c) Cytoplasmic domain of IL-27Ra is required for
sustained pSTAT1 activation. Left: Cartoon representation of receptor complexes. Right: STAT1 and STAT3 phosphorylation kinetics of RPE1 clones
stably expressing wt IL-27Ra and IL-27Ra-GP130 chimera after stimulation with IL-27 (10 nM, top panels) or after stimulation with HypIL-6 (20 nM,
bottom panels). Data was normalized to maximal levels for each cytokine and cell line. Data was obtained from two experiments with each two
technical replicates, showing mean ±std dev. (d) Phosphatases do not account for differential pSTAT1/3 activity induced by IL-27 and HypIL-6. Left:
Schematic representation of workflow using JAK inhibitor Tofacitinib. Right: MFI ratio of Tofacitinib-treated and non-treated RPE1 mXFPe-IL-27Ra cells
for pSTAT1 and pSTAT3 after stimulation with IL-27 (10 nM) and HypIL-6 (20 nM). Data was obtained from two experiments with each two technical
replicates, showing mean ± std dev.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Characterization of IL-27Ra mutants and probing phosphatase activity by Tofacitinib-mediated inhibition of JAK/STAT signaling.
Figure supplement 2. Effects of Cycloheximide-mediated inhibition of protein neosynthesis on IL-27 and HypIL-6 signaling.
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Figure 4. Unique and overlapping effects of IL-27 and HypIL-6 on the phosphoproteome of Th-1 cells. (a) Volcano plot of the phospho-sites regulated
(p value  0.05, fold change +1.5 or 1.5) by IL-27 (left) and HypIL-6 (right). Cells were stimulated for 15 min at saturating concentrations (IL-27: 10
nM, HypIL-6: 20 nM). Data was obtained from three biological replicates. (b) Heatmap representation (examples) of shared and differentially up- (left)
and downregulated (right) phospho-sites after IL-27 and HypIL-6 stimulation. Data represents the mean (log2) fold change of three biological replicates.
Figure 4 continued on next page
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UBR5 leads to ubiquitination and subsequent degradation of Rorgc (Rutz et al., 2015), the key tran-
scription factor required for Th-17 lineage commitment, thus limiting Th-17 differentiation (Fig-
ure 4—figure supplement 2d). A second example is PAK2, which phosphorylates and stabilizes
FoxP3 leading to higher levels of TReg cells (Figure 4—figure supplement 2d; O’Hagan et al.,
2017). Moreover, IL-27 stimulation led to a very strong phosphorylation of BCL2-associated agonist
of cell death (BAD), a critical regulator of T-cell survival and a well-known substrate of the PAK2
kinase (Ye and Field, 2012). Overall, our data show a large overlap between the IL-6 and IL-27 sig-
naling program, with a strong focus on JAK/STAT signaling. However, IL-27 engages additional sig-
naling intermediaries that could contribute to its unique immuno-modulatory activities. Further
studies will be required to assess how these IL-27 specific signaling pockets contribute to shape IL-
27 responses.
Kinetic decoupling of gene induction programs depends on sustained
STAT1 activation and IRF1 expression by IL-27
Next, we investigated how the different kinetics of STAT activation induced by HypIL-6 and IL-27
ultimately modulated gene expression by these two cytokines. To this end, we performed RNA-seq
analysis of Th-1 cells stimulated with HypIL-6 or IL-27 for 1 hr, 6 hr and 24 hr to obtain a dynamic
perspective of gene regulation. We identified ~12500 shared genes that could be quantified for all
three donors and throughout all tested experimental conditions. In a first step, we compared how
similar the gene programs induced by HypIL-6 and IL-27 were. Principal component analysis (PCA)
was run for a subset of genes, found to be significantly up- (total ~250) or downregulated
(total ~950) by either of the experimental conditions (p value0.05, fold change +2 or  2). At
one hour of stimulation HypIL-6 and IL-27 induced very similar gene programs, with the two cyto-
kines clustering together in the PCA analysis regardless of whether we focused on the subsets of
upregulated or downregulated genes (Figure 5a). However, the similarities between the two cyto-
kines changed dramatically in the course of continuous stimulation. While the two cytokines induced
the downregulation of comparable gene programs at 6 hr and 24 hr stimulation, as denoted by the
close clustering in the PCA analysis (Figure 5a, right panel) and the fraction of shared genes (~40%,
Figure 5b, Figure 5—figure supplement 1a–c, Figure 5—figure supplement 2a), this was not
observed for upregulated genes. Although the two cytokines induced comparable gene upregula-
tion programs after 1 hr of stimulation (~80% shared genes), this trend almost completely disap-
peared at later stimulation times (Figure 5a and b, Figure 5—figure supplement 2b). This is well-
reflected by the absolute numbers of up- or downregulated genes observed for IL-27 and HypIL-6
(Figure 5c). Stimulation with both cytokines yielded a similar trend of gene downregulation
(Figure 5c, right panel). However, while HypIL-6 stimulation resulted in a spike of gene upregulation
at 1 hr that quickly disappeared at later stimulation times, IL-27 stimulation was capable to increase
the number of upregulated genes beyond 6 hr of stimulation and maintains it even after 24 hr
(Figure 5c, left panel). This ‘kinetic decoupling’ of gene induction seems to have a striking functional
relevance. Gene set enrichment analysis (GSEA) (Liao et al., 2019) identified several reactome path-
ways to be enriched for IL-27 over the course of stimulation – most of them linked with Interferon
signaling and immune responses (Figure 5d). In contrast, for HypIL-6 stimulation no pathway enrich-
ment was detected. Most importantly, the vast majority of IL-27-induced genes that were associated
to these pathways belonged to genes upregulated by IL-27 treatment and that have been previously
Figure 4 continued
(c) Tyrosine and Serine phosphorylation of selected STAT proteins after stimulation with IL-27 (red) and HypIL-6 (blue). Two-tailed Student’s T-test:
*p<0.05, **p0.01,***p0.001; n.s., not significant. (d) pS727-STAT1 and pS727-STAT3 phosphorylation kinetics in Th-1 cells after stimulation with IL-27
or HypIL-6, normalized to maximal IL-27 stimulation. Data was obtained from three biological replicates with each two technical replicates, showing
mean ±std dev. (e) GO analysis ‘biological processes’ of the phospho-sites regulated by IL-27 (red) and HypIL-6 (blue) represented as bubble-plots. (f)
Phosphorylation of target proteins associated with STAT3/CDK transcription initiation complex after stimulation with IL-27 (blue) and HypIL-6 (red) and
schematic representation of transcription regulation of RNA polymerase II with identified phospho-sites (red flags). Two-tailed Student’s T-test: *p<0.05,
**p0.01,***p0.001; n.s., not significant.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Workflow for phospho-proteomics and cellular localization of identified phosphorylation targets.
Figure supplement 2. Phospho-proteomics - shared and unique targets and gene ontology analysis.
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Figure 5. Kinetic decoupling of gene induction programs depends on sustained STAT1 activation by IL-27. (a) Principal component analysis for genes
found to be significantly upregulated (left) or downregulated (right) for at least one of the tested conditions (time and cytokine). Data was obtained
from three biological replicates. (b) Kinetics of gene induction shared between IL-27 and HypIL-6 (relative to IL-27) for upregulated genes (red) or
downregulated genes (green). (c) Kinetics of gene numbers induced after IL-27 and HypIL-6 stimulation for upregulated genes (left) and downregulated
Figure 5 continued on next page
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linked to STAT1 activation (Satoh and Tabunoki, 2013; Rusinova et al., 2013; Figure 5—figure
supplement 2c). Although HypIL-6 treatment resulted in the induction of some of these genes, their
expression was very transient in time, in agreement with the short STAT1 activation kinetic profile
exhibited by HypIL-6 (Figure 5—figure supplement 2b and c).
Next, we performed cluster analysis to find further similarities and discrepancies between the
gene expression programs engaged by HypIL-6 and IL-27 (Figure 5e). Since genes downregulated
by IL-27 and HypIL-6 showed overall good similarity throughout the whole kinetic series, we mainly
focused on differences in upregulated gene induction. We identified three functionally relevant gene
clusters. The first gene cluster corresponds to genes that are transiently and equally induced by
HypIL-6 and IL-27. These genes peak after one hour and return to basal levels after 6 hr and 24 hr of
stimulation (Figure 5e). Interestingly, this cluster contains classical IL-6-induced and STAT3-depen-
dent genes, such as members of the NFkB and Jun/Fos transcriptional complex (Suh et al., 2008),
as well as the feedback inhibitor Suppressor Of Cytokine Signaling 3 (SOCS3) (Villarino et al., 2006)
and T-cell early activation marker CD69. (Figure 5e). A second cluster of genes corresponded to
genes that were persistently activated by IL-27 but only transiently by HypIL-6 (Figure 5e). Among
these genes we found classical STAT1-dependent genes, such as SOCS1, Programmed Cell Death
Ligand 1 (PDL1 = CD274) (Hirahara et al., 2012) and members of the interferon-induced protein
with tetratricopeptide repeats (IFIT) family. The third cluster of genes corresponded to genes exhib-
iting strong and sustained activation by IL-27 after 6 hr and 24 hr stimulation but no activation by
HypIL-6 at all. This ‘2nd wave’ of gene induction by IL-27 was almost exclusively comprised of classi-
cal Interferon Stimulated Genes (ISGs) (Figure 5—figure supplement 2c), such as STAT1 and 2,
Guanylate Binding Protein 1 (GBP1), GBP2, 4 and 5, and IRF8 and 9.
It is worth mentioning, that genes in the third cluster appear to require persistent STAT1 activa-
tion (Hu et al., 2002; Francois-Newton et al., 2012) and were the basis for the IFN signature identi-
fied in our reactome pathway analysis. Still, we were surprised about the magnitude of this 2nd gene
wave. Even though IL-27 exerts a sustained pSTAT1 kinetic profile, pSTAT1 levels were down
to ~10% of maximal amplitude after 3 hr of stimulation. We reasoned that additional factors could
further amplify the STAT1 response for IL-27 but not for HypIL-6. Within the 1st wave of STAT1-
dependent genes, we also spotted the transcription factor Interferon Response Factor 1 (IRF1), that
was continuously induced throughout the kinetic series in response to IL-27 but only transiently spik-
ing after 1 hr of HypIL-6 stimulation (Figure 5e). IRF1 expression was shown to prolong pSTAT1
kinetics (Zenke et al., 2018) and to be required for IL-27-dependent Tr-1 differentiation and func-
tion (Karwacz et al., 2017). We confirmed the kinetics of IRF1 protein expression by flow cytometry
and showed higher and more sustained protein levels after IL-27 stimulation relative to HypIL-6 (Fig-
ure 5—figure supplement 3a). Next, we tested in our RPE1 IL-27Ra cell system, whether siRNA-
mediated knockdown of IRF1 would alter the gene induction profiles of certain STAT1 or STAT3-
dependent marker genes. In RPE1 IL-27Ra cells, IRF1 protein levels were peaking around 6 hr after
stimulation with IL-27 and transfection with IRF1-targeting siRNA knocked down expression
by >80% (Figure 5—figure supplement 3b). Importantly, knockdown of IRF1 did not alter the over-
all kinetics of pSTAT1 and pSTAT3 activation (Figure 5—figure supplement 3c). Induction of
STAT1-dependent genes STAT1, GBP5, and OAS1 as well as STAT3-dependent gene SOCS3 were
followed by RT qPCR (Figure 5—figure supplement 3d). Interestingly, up to 6 hr of stimulation, the
gene induction curves were identical for control- and IRF1-siRNA treated cells. Later than 6 hr – that
is, when IRF1 protein levels are peaking – the gene induction was decreased between 40 and 70% in
absence of IRF1. Strikingly, expression of SOCS3, a classical STAT3-dependent reporter gene was
Figure 5 continued
genes (right). (d) GSEA reactome analysis of selected pathways with significantly altered gene induction in response to IL-27 or HypIL-6 stimulation.
Data represents the mean (log2) fold change of three biological replicates. (e) Cluster analysis comparing the gene induction kinetics after IL-27 or
HypIL-6 stimulation. Gene induction heatmaps for example genes as well as induction kinetics (mean) are shown for highlighted gene clusters. Data
represents the mean (log2) fold change of three biological replicates.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. IL-27 and HypIL-6 stimulated gene induction profiles represented as volcano plots.
Figure supplement 2. Kinetic decoupling of gene induction programs - shared and unique genes and GSEA pathway analysis.
Figure supplement 3. IL-27-induced upregulation of IRF1 amplifies induction of STAT1-dependent genes.
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transient and independent on IRF1 levels, highlighting that IRF1 selectively amplifies STAT1-depen-
dent gene induction. Taken together our data support a scenario whereby IL-27 by exhibiting a
kinetic decoupling of STAT1 and STAT3 activation is capable of triggering independent gene
expression waves, which ultimately contribute to shape its distinct biology.
IL-27-induced STAT1 response drives global proteomic changes in Th-1
cells
Next, we aimed to uncover how the distinct gene expression programs engaged by HypIL-6 and IL-
27 ultimately relate to alterations of the Th-1 cell proteome. For that, we continuously stimulated
SILAC -labeled Th-1 cells for 24 hr with saturating doses of IL-27 and HypIL-6 and compared quanti-
tative proteomic changes to unstimulated controls (Figure 6a). We quantified ~3600 proteins pres-
ent in all three biological replicates and in all tested conditions (unstimulated/IL-27/HypIL-6). Both
cytokines downregulated a similar number of proteins (IL-27: 57, HypIL-6: 52) (Figure 6b) with
approximately half of them being shared by the two cytokines, mimicking our observations in the
RNA-seq studies (Figure 6c, Figure 6—figure supplement 1). With 68 upregulated proteins, IL-27
was almost twice as potent as HypIL-6 (35 proteins) with very little overlap.
Among the upregulated proteins by IL-27 but not HypIL-6, we detected several proteins with
described immune-modulatory functions on T-cells. One of these proteins was Transforming Growth
Factor b (TGF-b), which is a key regulator with pleiotropic functions on T-cells (Yoshimura et al.,
2010). TGF-b has been identified to synergistically act with IL-27 to induce IL-10 secretion from Tr-1
cells – thus accounting for one of the key anti-inflammatory functions of IL-27 (Awasthi et al., 2007).
On the other hand, we also found SELPLG-encoded protein RSGL-1 which is critically required for
efficient migration and adhesion of Th-1 cells to inflamed intestines (Brown et al., 2012;
Matsumoto et al., 2007). Interestingly, we found LARP7 moderately upregulated by IL-27. This neg-
ative regulator for RNA pol II was also identified in our phospho-target screening and selectively
engaged by IL-27 (Figure 4f). IL-27 and HypIL-6 share ~60% of downregulated proteins, but without
strong functional patterns. Both cytokines downregulated several proteins related to mitotic cell
cycle (LIG1, CSNK2B, PSMB1) mRNA processing and splicing (NCBP2, PCBP2, NUDT21)
(Slenter et al., 2018).
Strikingly, a significant number (~40%) of proteins upregulated by IL-27 belong to the group of
ISGs (Figure 6b and c, Figure 6—figure supplement 1b). This particular set of proteins including
STAT1, STAT2, MX Dynamin like GTPase 1 (MX1), Interferon Stimulated Gene 20 (ISG20) or Poly
(ADP-Ribose) Polymerase Family Member 9 (PARP9) was not markedly altered by HypIL-6. Of note:
the overall expression patterns of the most significantly altered proteins are congruent to the gene
induction patterns observed after 6 hr and 24 hr (Figure 6d and e, Supp. Fig. 10b). Similar to this,
GSEA reactome analysis identified again pathways associated with interferon signaling and cytokine/
immune system but failed to detect any significant functional enrichment by HypIL-6 (Figure 6e, Fig-
ure 6—figure supplement 1b & c). Finally, we correlated RNAseq-based gene induction patterns
with detected proteomic changes. To our surprise, we only found a relatively low number of shared
hits. However, the identified proteins belong exclusively to a group upregulated by IL-27
(Figure 6f). They are all located in the ‘2nd gene wave’ cluster and all of them are regulated by ISGs
(Figure 5e). Taken together these results provide compelling evidence that sustained pSTAT1 acti-
vation by IL-27 accounts for its gene induction and proteomic profiles, thus, giving a mechanistic
explanation for the diverse biological outcomes of IL-27 and IL-6. Our observations are in good
agreement with previous findings in cancer cells, showing that particularly the involvement of STAT1
activation is responsible for proteomic remodeling by IL-27 (Petretto et al., 2016).
Receptor and STAT concentrations determine the nature of the IL-6/IL-
27 response
Our data suggest that STAT molecules compete for binding to a limited number of phospho-Tyr
motifs in the intracellular domains of cytokine receptors. A direct consequence derived from this
hypothesis is that cells can adjust and change their responses to cytokines by altering their concen-
trations of specific STATs or receptors molecules. To assess to what degree immune cells differ in
their expression of cytokine receptors and STATs, we investigated levels of IL-6Ra, GP130, IL-27Ra,
STAT1, and STAT3 protein expression across different immune cell populations making use of the
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Figure 6. IL-27-induced STAT1 response drives global proteomic changes in Th-1 cells. (a) Workflow for quantitative SILAC proteomic analysis of Th-1
cells continuously stimulated (24 hr) with IL-27 (10 nM), HypIL-6 (20 nM) or left untreated. (b) Global proteomic changes in Th-1 cells induced by IL-27
(left) or HypIL-6 (right) represented as volcano plots. Proteins significantly up- or downregulated are highlighted in red (p value  0.05, fold
change +1.5 or 1.5). Significantly altered ISG-encoded proteins by IL-27 are highlighted in yellow. Data was obtained from three biological
Figure 6 continued on next page
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Immunological Proteomic Resource (ImmPRes - http://immpres.co.uk) database. Strikingly, the level
of expression of these proteins change dramatically across the populations studied (Figure 7a), sug-
gesting that these cells could potentially produce very different responses to HypIL-6 and IL-27
stimulation.
In order to quantify (and predict) how changes in expression levels of different proteins modify
the kinetics of pSTAT, we made use of the two mathematical models of HypIL-6 and IL-27 stimula-
tion and the parameters inferred with Bayesian methods. Our mathematical models could accurately
reproduce the experimental results generated across our study, that is, signaling by the IL-27Ra chi-
meric and IL-27Ra-Y616F mutant receptors and dose/response studies (Figure 7—figure supple-
ment 1a–c), making use of the posterior parameter distributions generated from the Bayesian
parameter calibration. Having developed mathematical models which are able to accurately explain
the experimental data (Figure 3—figure supplement 1c and d) and reproduce independent experi-
ments (Figure 3b and c), we then sought to use the models to predict pSTAT signaling kinetics
under different concentration regimes of receptors and STATs. To simplify the simulations, we
focused our analysis in GP130 and STAT1 proteins, two of the proteins that greatly vary in the differ-
ent immune populations (Figure 7a). As baseline values for the concentrations GP130 0ð Þ½ ,
IL27Ra 0ð Þ½ , STAT1 0ð Þ½  and STAT3 0ð Þ½  we used approximately the median values from the posterior
distributions for each parameter: GP130 0ð Þ½  ¼ 25nM, IL27Ra 0ð Þ½  ¼ 50 nM
and STAT1 0ð Þ½  ¼ STAT3 0ð Þ½  ¼ 500 nM. To see the effect of varying GP130 concentrations on pSTAT
signaling, we decreased the initial concentration of GP130 and simulated the model using the
accepted parameters sets from the ABC-SMC to inform the other parameter values. A tenfold reduc-
tion on GP130 concentration GP130 0ð Þ½  ¼ 2:5nMð Þ resulted in a striking loss in pSTAT1 levels
induced by HypIL-6, with very little effect on pSTAT3 levels induced by this cytokine (Figure 7b).
pSTAT1/3 kinetics induced by IL-27, however, was not affected by this decrease in GP130 concentra-
tion (Figure 7b). Interestingly, the HypIL-6 signaling profile predicted by our model at low GP130
concentrations strongly resemble the one induced by HypIL-6 in Th-1 cells (Figure 1c), where very
low levels of GP130 are found, further confirming the robustness of the predictions generated by
our mathematical models. When the concentration of STAT1 was increased by a factor of ten
STAT1 0ð Þ½  ¼ 5000 nM, both HypIL-6 and IL-27 induced significantly higher levels of pSTAT1 activa-
tion (Figure 7b). pSTAT3 levels were not affected for HypIL-6 stimulation but were decreased for IL-
27 stimulation (Figure 7b), further indicating the competitive nature of the binding of STAT1 and
STAT3 to IL-27Ra and GP130. Overall, our mathematical model predicts that changes on GP130 and
STAT1 expression produce a substantial remodeling of the HypIL-6 and IL-27 signalosome, which
ultimately could lead to aberrant responses.
STAT1 protein levels in SLE patients modify HypIL-6 and IL-27 signaling
responses
STAT1 is a classical IFN responsive gene and STAT1 levels are highly increased in environments rich
in IFNs (Wong et al., 1998). Thus, we next ask whether STAT1 levels would be increased in SLE
patients, an example of disease where IFNs have been shown to correlate with a poor prognosis,
making use of available gene expression datasets (Tokuyama et al., 2018). We did not find differen-
ces in the expression of GP130, IL-6Ra or IL-27Ra in SLE patients (Figure 7—figure supplement
2a). However, we detected a considerable increase in the levels of STAT1 and STAT3 transcripts in
these patients when compared to healthy controls, with the increase on STAT1 expression being
Figure 6 continued
replicates. (c) Venn diagrams comparing unique upregulated (left) and downregulated (right) proteins by IL-27 (blue) and HypIL-6 (red) as well as shared
altered proteins. ISG-encoded proteins are highlighted in yellow. (d) Heatmaps of the top 30 up- and downregulated proteins by IL-27 compared to
HypIL-6. Data representation of the mean (log2) fold change of three biological replicates. (e) Heatmap representation and enrichment plot of proteins
identified by GSEA reactome pathway enrichment analysis ‘Cytokine signaling and immune system’ induced by IL-27. Data representation of the mean
(log2) fold change of three biological replicates. (f) Correlation of IL-27 and HypIL-6-induced RNA-seq transcript levels (+2 or  2 fold change) with
quantitative proteomic data (+1.5 or 1.5 fold change). Data representation of the mean (log2) fold change of three biological replicates.
The online version of this article includes the following figure supplement(s) for figure 6:
Figure supplement 1. Shared and unique proteomic changes upon IL-27 and HypIL-6 stimulation and GSEA pathway reactome analysis.
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Figure 7. Receptor and STAT concentrations determine the nature of the cytokine response. (a) Copy numbers of indicated proteins determined for
different T-cell subsets using mass-spectrometry-based proteomics (ImmPRes - http://immpres.co.uk). (b) Model predictions for varying levels of STAT1
and STAT3 (left panel) or IL-27Ra and GP130 (right panel) for phosphorylation kinetics of STAT1 and STAT3. (c) Gene expression profiles determined by
RNAseq analysis comparing indicated genes of a cohort of SLE risk patients with a cohort of healthy controls. Data obtained from: Proc Natl Acad Sci U
Figure 7 continued on next page
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significantly more pronounced (Figure 7c). Since our mathematical model predicted that increases in
STAT1 expression could significantly change cytokine-induced cellular responses by HypIL-6 and IL-
27, we next experimentally tested this prediction. For that, we primed Th-1 cells with IFNa2 over-
night to increase total STAT1 levels (and to a lower extent STAT3) in these cells (Figure 7—figure
supplement 2b). While both HypIL-6 and IL-27 induced comparable levels of pSTAT3 in primed and
non-primed Th-1 cells, levels of pSTAT1 induced by the two cytokines were significantly upregulated
in primed Th-1 cells, resulting in a bias STAT1 response and confirming our model predictions
(Figure 7d). We next investigated whether this bias STAT1 activation by HypIL-6 and IL-27 observed
in IFNa2-primed Th-1 cells was also present in SLE patients. For that we collected PBMCs from six
SLE patients or five age-matched healthy controls and measured STAT1 and STAT3 expression, as
well as pSTAT1 and pSTAT3 induction by HyIL-6 and IL-27 after 15 min treatments in CD4 T cells.
Importantly, comparable results to those obtained with IFN-primed Th-1 cells were obtained, with
signaling bias toward pSTAT1 in CD4 +T cells from SLE patients stimulated with HypIL-6 and IL-27
(Figure 7e, Figure 7—figure supplement 2c & d), further supporting the fact that STAT concentra-
tions play a critical role in defining cytokine responses in autoimmune disorders.
Our data show that STAT1 and STAT3 compete for phospho-Tyr motifs in GP130, with STAT3
having an advantage resulting from its tighter affinity to GP130. Finally, we asked whether crippling
JAK activity by using sub-saturating doses of JAK inhibitors could differentially affect STAT1 and
STAT3 activation by HypIL-6 and therefore rescue the altered cytokine responses found in SLE
patients. To test this, RPE1 and Th-1 cells were stimulated with saturated concentrations of HypIL-6
and titrating the concentrations of Tofacitinib, a clinically approved JAK inhibitor. Strikingly, Tofaciti-
nib inhibited HypIL-6 induced pSTAT1 more efficiently than pSTAT3 in both RPE1 IL-27Ra cells and
Th-1 cells (Figure 7f). At 50 nM concentration, Tofacitinib inhibited pSTAT1 levels induced by HypIL-
6 by 60%, while only inhibited pSTAT3 levels by 30% (Figure 7f) – an effect that we did not observe
for IL-27 stimulation. Overall, our results show that the changes in STATs concentration found in
autoimmune disorders shape cytokine signaling responses and could contribute to disease
progression.
Discussion
Cytokine pleiotropy is the ability of a cytokine to exert a wide range of biological responses in differ-
ent cell types. This functional pleiotropy has made the study of cytokine biology extremely challeng-
ing given the strong crosstalk and shared usage of key components of their signaling pathways,
leading to a high degree of signaling plasticity, yet still allowing functional selectivity
(Garbers et al., 2012; Kang et al., 2020). Here, we aimed to identify the underlying determinants
that define cytokine functional selectivity by comparing IL-27 and IL-6 at multiple scales – ranging
from cell surface receptors to proteomic changes. We show that IL-27 triggers a more sustained
STAT1 phosphorylation than IL-6, via a high-affinity STAT1/IL-27Ra interaction centered around
Tyr613 on IL-27Ra. This in turn results in a more sustained IRF1 expression induced by IL-27, which
leads to the upregulation of a second wave of gene expression unique to IL-27 and comprised of
classical ISGs. We go one step further and show that this strong receptor/STAT coupling is altered in
autoimmune disorders where STATs concentrations are often dysregulated. Increased expression of
Figure 7 continued
S A 115, 12565–12572. Two-tailed Student’s T-test: *p<0.05, **p0.01,***p0.001; n.s., not significant. (d) Dose-dependent phosphorylation of STAT1
and STAT3 as a response to IL-27 and HypIL-6 stimulation in naive and IFNa2-primed (2 nM, 24 hr) Th-1 cells, normalized to maximal IL-27 stimulation
(ctrl). Data was obtained from four biological replicates with each two technical replicates, showing mean ±std dev. (e) Phosphorylation of STAT1 (left)
and STAT3 (right) as a response to IL-27 (2 nM, 15 min) and HypIL-6 (10 nM, 15 min) stimulation in healthy control (ctrl) and SLE patient CD4 +T cells.
Data was obtained from five healthy control donors (Diveu et al., 2009) and six SLE patients. Two-tailed Student’s T-test: *p<0.05, **p0.01,
***p0.001; n.s., not significant. (f) Tofacitinib titration to inhibit STAT1 and STAT3 phosphorylation by IL-27 (top, 2 nM, 15 min) HypIL-6 (bottom, 10
nM, 15 min) in Th-1 cells (left) and RPE1 IL-27Ra cells (right). Data was obtained from three donors with each two technical replicates (Th-1) and two
biological experiments (RPE1 IL-27Ra cells) with each two technical replicates, showing mean ±std dev.
The online version of this article includes the following figure supplement(s) for figure 7:
Figure supplement 1. Validation of mathematical models for signaling kinetics of IL-27Ra receptor chimera and Y613F mutant.
Figure supplement 2. Altered total STAT levels and biased pSTAT1/pSTAT3 response in SLE.
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STAT1 in SLE patients’ biases HypIL-6 and IL-27 responses toward STAT1 activation, further contrib-
uting to the worsening of the disease. By using suboptimal doses of the JAK inhibitor Tofacitinib, we
show that specific STAT proteins engaged by a given cytokine can be targeted.
The tight coupling of one receptor subunit to one particular STAT that we have identified in our
study is a rather unusual phenomenon for heterodimeric cytokine receptor complexes, which has
been first suggested by Owaki et al., 2008. Generally, the entire signaling output driven by a cyto-
kine-receptor complex emanates from a dominant receptor subunit, which carries several Tyr resi-
dues susceptible of being phosphorylated (Umeshita-Suyama et al., 2000; Nadeau et al., 1999).
This in turn results in competition between different STATs for binding to shared phospho-Tyr motifs
in the dominant receptor chain, leading to different kinetics of STAT phosphorylation as observed
for IL-6 stimulation (Rolvering et al., 2017; Figure 1b). Moreover, this localized signaling quantum
allows phosphatases and feedback regulators – induced upon cytokine stimulation – to act in syn-
ergy to reset the system to its basal state, generating a very synchronous and coordinated signaling
wave. Although very effective, this molecular paradigm presents its limitations. STAT competition for
the same pool of phospho-Tyr makes the system very sensitive to changes in STAT concentration.
IFNg-primed cells, which exhibit increased STAT1 levels, trigger an IFNg-like STAT1 response upon
IL-6 stimulation (Costa-Pereira et al., 2002). IL-10 anti-inflammatory properties are lost in cells with
high levels of STAT1 expression, as a result of a pro-inflammatory environment rich in IFNs
(Sharif et al., 2004). Indeed, we show that STAT1 transcripts levels are increased in Crohn’s disease
and SLE patients and they contributed to alter IL-6 responses. Strikingly, IL-27 appears to have
evolved away from this general model of cytokine signaling activation. Our results show that STAT1
activation by IL-27 is tightly coupled to IL-27Ra, while STAT3 activation by this cytokine mostly
depends on GP130. This decoupled STAT1 and STAT3 activation by IL-27 is possible thanks to the
presence of a putative high-affinity STAT1 binding site on IL-27Ra that resembles the one present in
IFNgR1 (Pflanz et al., 2004). As a result of this, IL-27 can trigger sustained and independent phos-
phorylation of both STAT1 and STAT3. This IL-27 feature allows it to induce robust responses in
dynamic immune environments. Indeed, our mathematical models of cytokine signaling, and Bayes-
ian inference, together with the experimental observations show that changes in receptor concentra-
tion minimally affected pSTAT1/3 induced by IL-27, while they fundamentally alter IL-6 responses.
Overall, our data show that cytokine responses are versatile and adapt to the continuously changing
cell proteome, highlighting the need to measure cytokine receptors and STATs expression levels, in
addition to cytokine levels, in disease environments to better understand and predict altered
responses elicited by dysregulated cytokines.
In recent years, it has become apparent that the stability of the cytokine-receptor complex influ-
ences signaling identity by cytokines (Richter et al., 2017). Short-lived complexes activate less effi-
ciently those STAT molecules that bind with low-affinity phospho-Tyr motif in a given cytokine
receptor (Martinez-Fabregas et al., 2019). Our current results further support this kinetic discrimi-
nation mechanism for STAT activation. Our statistical inference identified differences in STAT recog-
nition to the cytokine receptor phospho-Tyr motifs as one of the major determinants of STAT
phosphorylation kinetics. This parameter alone was sufficient to explain transient and sustained
STAT1 phosphorylation induced by IL-6 and IL-27, respectively, without the need to invoke the
action of phosphatases or negative feedback regulators such as SOCSs. Indeed, our results indicate
that the rate of STAT1 dephosphorylation is similar between the IL-6 and IL-27 systems, suggesting
that phosphatases do not contribute to these early kinetic differences. Moreover, blocking protein
translation, and therefore the upregulation of negative feedback regulators by IL-6 treatment did
not result in a more sustained STAT1 phosphorylation by IL-6, again indicating that the transient
kinetics of STAT1 phosphorylation by IL-6 is encoded at the receptor level and does not require fur-
ther regulation. However, recent reports have found that the amplitude of STAT1 phosphorylation in
response to IL-6 is regulated by levels of PTPN2 expression, suggesting that phosphatases can play
additional roles in shaping IL-6 responses beyond controlling the kinetics of STAT activation
(Twohig et al., 2019). STAT1 phosphorylation levels by IL-27 on the other hand were significantly
more sustained in the absence of protein translation, suggesting that negative feedback mechanisms
are required to downmodulate signaling emanating from high-affinity STAT-receptor interactions.
Overall, our results suggest that while phosphatases and negative feedback regulators play an
important role in maintaining cytokine signaling homeostasis (Heinrich et al., 2003), the kinetics of
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STAT activation appears to be already encoded at the level of receptor engagement, thus ensuring
maximal efficiency and signal robustness.
Cytokine signaling plasticity can occur at the level of receptor activation. In the past years, a sce-
nario has emerged suggesting that the absolute number of signaling active receptor complexes is a
critical determinant for signal output integration. Accordingly, specific biological responses were
shown to be tuned either by abundance of cell surface receptors (Levin et al., 2011; Moraga et al.,
2009) or by the level of receptor assembly (Martinez-Fabregas et al., 2019; Wilmes et al., 2015;
Ho et al., 2017). Here, we show for the first time that IL-27-induced dimerization of IL-27Ra and
GP130 at the cell surface of live cells – in good agreement with previous studies on heterodimeric
cytokine receptor systems (Wilmes et al., 2015; Richter et al., 2017). For IL-27, the receptor subu-
nits IL-27Ra and GP130 can be expressed at different ratios as seen for naive vs. activated T-cells
(Charlot-Rabiega et al., 2011) as well as intestinal cells (Diegelmann et al., 2012). On T-cells, par-
ticularly after activation, IL-27Ra is expressed in strong excess over GP130, rendering GP130 as the
limiting factor for receptor complex assembly (Pflanz et al., 2004). Interestingly, we observe that in
addition to a faster kinetic of STAT1 phosphorylation, HypIL-6 treatment induces a lower maximal
amplitude in pSTAT1 activation in T cells. This is in stark contrast to our results in RPE1 cells, where
high abundance of GP130 (~3000–4000 copies of cell surface GP130) is found. In these cells, both
cytokines elicited similar amplitudes of STAT1 phosphorylation. Our results suggest that surface
receptor density in synergy with STATs binding dynamics to phospho-Tyr motif on cytokine recep-
tors act to define the amplitude and kinetics of STAT activation in response to cytokine stimulation.
The distinct STAT1 and STAT3 kinetic profiles induced by IL-6 and IL-27 are the prerequisite for
time-correlated decoupling of genetic programs: a ‘shared GP130/STAT3-dependent wave’ and an
IL-27-‘unique IL-27Ra/STAT1-dependent wave’. However, pSTAT1 levels induced by IL-27 at 3 hr
were down to ~10% of maximal amplitude, suggesting that additional factors would be required to
amplify the initial STAT1 response elicited by IL-27. We observed that IL-27 induces the expression
of an early wave of classical STAT1-dependent genes, which is also shared by IL-6. However, while
IL-27 induces the upregulation of these genes throughout the entire duration of the experiment, IL-6
only resulted in a transient spike. We reasoned that this additional factor required for IL-27 signal
amplification would be among these early STAT1-dependent genes. Among this set of genes we
found the transcription factor IRF1, which had been shown to act as a feedback amplificant for
pSTAT1 activity (Zenke et al., 2018). Importantly, IRF1 protein levels have been shown to be upre-
gulated in response to IL-27 and IFNg but not to IL-6 stimulation in hepatocytes (Bender et al.,
2009). IRF1 plays a key role in chromatin accessibility which is critically required for IL-27-induced
differentiation of Tr-1 cells and subsequent IL-10 secretion (Karwacz et al., 2017). Here, we could
prove that the contribution of IRF1 on STAT1- but not STAT3-dependent genes is a generic feature
of IL-27 signaling. This readily explains the significant transcriptomic overlap of IL-27 with type I
(Imamichi et al., 2012) or type II interferons (Rolvering et al., 2017) after long-term stimulation with
these cytokines. Along this line, it is not surprising that IL-27 – beyond its well-described effects on
T-cell development – can also mount a considerable antiviral response as shown in hepatic cells and
PBMCs (Fakruddin et al., 2007; Frank et al., 2010). Our results suggest that by modulating the
kinetics of STAT phosphorylation, cytokines can modulate the expression of accessory transcription
factors, such as IRF1, that act in synergy with STATs to fine-tune gene expression and provide func-
tional diversity.
Data availability
Python (version 3.7) codes for the ABC-SMC model selection and parameter inference can be found
in the public repository https://github.com/PollyJeffrey/Cytokine_modelling (copy archived at swh:1:
rev:9c3e0ddc7a96eac941baad560d1541d660b0515d; Wilmes, 2021), along with the results of the
analysis. Phospho-proteomic and proteomic datasets were uploaded to the Proteome Exchange
platform with accession numbers PXD024657 and PXD024188 respectively. RNA-seq dataset was
uploaded in the GSE database with accession number GSE164479.
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Materials and methods
Protein expression and purification
Murine IL-27 was cloned as a linker-connected single-chain variant (p28 +EBI3) as described in
Oniki et al., 2006. Human HyperIL-6 (HypIL-6), and murine single-chain IL-27 were cloned into the
pAcGP67-A vector (BD Biosciences) in frame with an N-terminal gp67 signal sequence and a C-ter-
minal hexahistidine tag, and produced using the baculovirus expression system, as described in
LaPorte et al., 2008. Baculovirus stocks were prepared by transfection and amplification in Spodop-
tera frugiperda (Sf9) cells grown in SF900II media (Invitrogen) and protein expression was carried
out in suspension Trichoplusiani ni (High Five) cells grown in InsectXpress media (Lonza).
Purification was performed using the method described in Spangler et al., 2019. For IL-27, the
cells were pelleted with centrifugation at 2000 rpm, prior to a precipitation step through addition of
Tris pH 8.0, CaCl2 and NiCl2 to final concentrations of 200 mM, 50 mM and 1 mM, respectively. The
precipitate formed was then removed through centrifugation at 6000 rpm. Nickel-NTA agarose
beads (Qiagen) were added and the target proteins purified through batch binding followed by col-
umn washing in HBS-Hi buffer (HBS buffer supplemented to 500 mM NaCl and 5% glycerol, pH 7.2).
Elution was performed using HBS-Hi buffer plus 200 mM imidazole. Final purification was performed
by size exclusion chromatography on an ENrich SEC 650 300 column (Biorad), again equilibrated in
HBS-Hi. Concentration of the purified sample was carried out using 10 kDa Millipore Amicon-Ultra
spin concentrators. For HypIL-6, proteins were purified likewise, but in 10 mM HEPES (pH 7.2) con-
taining 150 mM NaCl. Recombinant cytokines were purified to greater than 98% homogeneity.
For cell surface labeling, the anti-GFP nanobody (NB) ‘enhancer’ and ‘minimizer’ were used,
which bind mEGFP with subnanomolar binding affinity (Kirchhofer et al., 2010). NB was cloned into
pET-21a with an additional cysteine at the C-terminus for site-specific fluorophore conjugation in a
1:1 fluorophore:nanobody stoichiometry. Furthermore, (PAS)5 sequence to increase protein stability
and a His-tag for purification were fused at the C-terminus. Protein expression in E. coli Rosetta
(DE3) and purification by immobilized metal ion affinity chromatography was carried out by standard
protocols. Purified protein was dialyzed against HEPES pH 7.5 and reacted with a twofold molar
excess of DY647 maleimide (Dyomics), ATTO 643 maleimide (AT643) and ATTO Rho11 maleimide
(Rho11) (ATTO-TEC GmbH), respectively. After 1 hr, a threefold molar excess (with respect to the
maleimide) of cysteine was added to quench excess dye. Protein aggregates and free dye were sub-
sequently removed by size exclusion chromatography (SEC). A labeling degree of 0.9-1:1 fluoro-
phore:protein was achieved as determined by UV/Vis spectrophotometry.
CD4 +T cell purification and Th-1 differentiation
Human buffy coats were obtained from the Scottish Blood Transfusion Service and peripheral blood
mononuclear cells (PBMCs) of healthy donors were isolated from buffy coat samples by density gra-
dient centrifugation according to manufacturer’s protocols (Lymphoprep, STEMCELL Technologies).
From each donor, 100  106 PBMCs were used for isolation of CD4 +T cells. Cells were decorated
with anti-CD4FITC antibodies (Biolegend, #357406) and isolated by magnetic separation according to
manufacturer’s protocols (MACS Miltenyi) to a purity >98% CD4+. Freshly isolated resting CD4+ T
cells (3  107 per donor) were activated under Th-1 polarizing conditions using ImmunoCult Human
CD3/CD28 T Cell Activator (StemCell, Cat#10971) following manufacturer instructions for 3 days in
RPMI-1640, 10% v/v FBS, 100 U/ml penicillin-streptomycin (Gibco) in the presence of the cytokines
IL-2 (Novartis, #709421, 20 ng/ml), anti-IL-4 antibody (10 ng/ml, BD Biosciences, #554481), IL-12 (20
ng/ml, BioLegend, #573002). After 3 days of priming, cells were expanded for another 5 days in the
presence of IL-2 (20 ng/ml).
Human SLE patient samples
This study was authorized by the French Competent Authority dealing with Research on Human Bio-
logical Samples namely the French Ministry of Research. The Authorization number is ECH 19/04. To
issue such authorization, the Ministry of Research has sought the advice of an independent ethics
committee, namely the ‘Comité de Protection des Personnes,’ which voted positively, and all
patients gave their written informed consent. The healthy volunteer was recruited to serve as healthy
control individuals. Healthy and patients’ blood samples were collected in heparinized tubes (BD
Wilmes, Jeffrey, et al. eLife 2021;10:e66014. DOI: https://doi.org/10.7554/eLife.66014 24 of 44
Research article Computational and Systems Biology Immunology and Inflammation
Vacutainer 368886, BD Biosciences San Jose, CA, USA) and PBMC samples were isolated using Ficoll
(Pancoll, Pan Biotech #P04-60500) density gradient centrifugation. The isolated PBMCs were washed
with PBS and the remaining red blood cells were lysed using RBC lysis buffer (ACK lysing buffer,
Gibco #A10492-01), incubate 3 min at room temperature. Cells were washed in PBS and resuspend
the cells with 1 ml of freezing medium (with DMSO, PAN Biotech, #P07-90050) and transfer the cells
in a cryotube. cryotube in a Freezing container (Nalgene) and at  80˚C and then transferred into liq-
uid nitrogen container for long-term storage.
Classification and demographic information about SLE patients and
healthy controls
SLE patients were included if they fulfilled the American College of Rheumatology (ACR) Classifica-
tion Criteria Hochberg MC. Updating the American College of Rheumatology revised criteria for the
classification of systemic lupus erythematosus (Hochberg, 1997). Exclusion criteria were current
intake of 10 mg or more of prednisone or equivalent and/or use of immunosuppressants within the
previous 6 months before inclusion. Use of hydroxychloroquine was not an exclusion criterion.
Patients were mostly in clinical remission, half with biological remission, half with persistent anti
native DNA autoantibodies. All SLE patients and healthy controls were females between 41 and 58
years old.
(Phospho-) Proteomics
For (phospho-) proteomic experiments, Th-1 cells from each donor were split into three different
conditions after initial expansion: Light SILAC media (40 mg/ml L-Lysine K0 (Sigma, #L8662) and 84
mg/ml L-Arginine R0 (Sigma, #A8094)), medium SILAC media (49 mg/ml L-Lysine U-13C6 K6
(CKGAS, #CLM-2247–0.25) and 103 mg/ml L-Arginine U-13C6 R6 (CKGAS, #CLM-2265–0.25)) and
heavy SILAC media (49.7 mg/ml L-Lysine U-13C6,U-15N2 K8 (CKGAS, #CNLM-291-H-0.25) and
105.8 mg/ml L-Arginine U-13C6,U-15N2 R10 (CKGAS, #CNLM-539-H-0.25)) prepared in RPMI SILAC
media (Thermo Scientific, #88365) supplemented with 10% dialyzed FBS (HyClone, #SH30079.03), 5
ml L-Glutamine (Invitrogen, #25030024), 5 ml Pen/Strep (Invitrogen, #15140122), 5 ml MEM vitamin
solution (Thermo Scientific, #11120052), 5 ml Selenium-Transferrin-Insulin (Thermo Scientific,
#41400045) and expanded in the presence of 20 ng/ml IL-2 and 10 ng/ml anti-IL4 for another 10
days in order to achieve complete labeling. Media was exchanged every 2 days. Incorporation of
medium and heavy version of Lysine and Arginine was checked by mass spectrometry and samples
with an incorporation greater than 95% were used.
After expansion, cells were starved without IL-2 for 24 hr before stimulation with 10 nM IL-27 or
20 nM HyIL-6 for 15 min (phosphoproteomics) or 24 hr (global proteomic changes). Cells were then
washed three times in ice-cold PBS, mix in a 1:1:1 ratio, resuspended in SDS-containing lysis buffer
(1% SDS in 100 mM Triethylammonium Bicarbonate buffer (TEAB)) and incubated on ice for 10 min
to ensure cell lysis. Then, cell lysates were centrifuged at 20,000 g for 10 min at +4˚C and superna-
tant was transferred to a clean tube. Protein concentration was determined by using BCA Protein
Assay Kit (Thermo, #23227), and 10 mg of protein per experiment were reduced with 10 mM dithio-
threitol (DTT, Sigma, #D0632) for 1 hr at 55˚C and alkylated with 20 mM iodoacetamide (IAA, Sigma,
#I6125) for 30 min at RT. Protein was then precipitated using six volumes of chilled ( 20˚C) acetone
overnight. After precipitation, protein pellet was resuspended in 1 ml of 100 mM TEAB and digested
with Trypsin (1:100 w/w, Thermo, #90058) and digested overnight at 37˚C. Then, samples were
cleared by centrifugation at 20000 g for 30 min at +4˚C, and peptide concentration was quantified
with Quantitative Colorimetric Peptide Assay (Thermo, #23275).
Phosphopeptide enrichment in the peptide fractions generated as described above was carried
out using MagResyn Ti-IMAC following manufacturer instructions (2BScientific, MRTIM002).
High pH reverse phase fractionation for phosphoproteomics
Samples were dissolved in 200 mL of 10 mM ammonium formate buffer pH 9.5 and peptides are frac-
tionated using high pH RP chromatography. A C18 Column from Waters (XBridge peptide BEH, 130
Å, 3.5 mm 4.6  150 mm, Ireland) with a guard column (XBridge, C18, 3.5 mm, 4.6  20 mm, Waters)
are used on an Ultimate 3000 HPLC (Thermo-Scientific). Buffers A and B used for fractionation con-
sist, respectively of 10 mM ammonium formate in milliQ water (Buffer A) and 10 mM ammonium
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formate in 90% acetonitrile (Buffer B), both buffers were adjusted to pH 9.5 with ammonia. Fractions
are collected using a WPS-3000FC autosampler (Thermo-Scientific) at 1 min intervals. Column and
guard column were equilibrated with 2% buffer B for 20 min at a constant flow rate of 0.8 ml/min
and a constant temperature 0 f 21˚C. Samples (193 ml) are loaded onto the column at 0.8 ml/min,
and separation gradient started from 2% buffer B, to 8% B in 6 min, then from 8% B to 45% B within
54 min and finally from 45% B to 100% B in 5 min. The column is washed for 15 min at 100% buffer
B and equilibrated at 2% buffer B for 20 min as mentioned above. The fraction collection started 1
min after injection and stopped after 80 min (total of 80 fractions, 800 ml each). Each peptide fraction
was acidified immediately after elution from the column by adding 20–30 ml 10% formic acid to each
tube in the autosampler. The total number of fractions concatenated was set to 10. The content of
fractions from each set was dried prior to further analysis.
LC-MS/MS analysis
LC-MS analysis was done at the FingerPrints Proteomics Facility (University of Dundee). Analysis of
peptide readout was performed on a Q Exactive plus, Mass Spectrometer (Thermo Scientific) cou-
pled with a Dionex Ultimate 3000 RS (Thermo Scientific). LC buffers used are the following: buffer A
(0.1% formic acid in Milli-Q water (v/v)) and buffer B 80% acetonitrile and 0.1% formic acid in Milli-Q
water (v/v). Dried fractions were resuspended in 35 ml, 1% formic acid and aliquots of 15 ml of each
fraction were loaded at 10 ml/min onto a trap column (100 mm  2 cm, PepMap nanoViper C18 col-
umn, 5 mm, 100 Å, Thermo Scientific) equilibrated in 0.1% TFA. The trap column was washed for 5
min at the same flow rate with 0.1% TFA and then switched in-line with a Thermo Scientific, resolving
C18 column (75 mm  50 cm, PepMap RSLC C18 column, 2 mm, 100 Å). The peptides were eluted
from the column at a constant flow rate of 300 nl/min with a linear gradient from 2% buffer B to 5%
buffer B in 5 min then from 5% buffer B to 35% buffer B in 125 min, and finally from 35% buffer B to
98% buffer B in 2 min. The column was then washed with 98% buffer B for 20 min and re-equili-
brated in 2% buffer B for 17 min. The column was kept at a constant temperature of 50˚C. Q-exac-
tive plus was operated in data dependent positive ionization mode. The source voltage was set to
2.5 Kv and the capillary temperature was 250˚C.
A scan cycle comprised MS1 scan (m/z range from 350 to 1600, ion injection time of 20 ms, reso-
lution 70,000 and automatic gain control (AGC) 1  106) acquired in profile mode, followed by 15
sequential dependent MS2 scans (resolution 17500) of the most intense ions fulfilling predefined
selection criteria (AGC 2  105, maximum ion injection time 100 ms, isolation window of 1.4 m/z,
fixed first mass of 100 m/z, spectrum data type: centroid, intensity threshold 2  104, exclusion of
unassigned, singly and >7 charged precursors, peptide match preferred, exclude isotopes on,
dynamic exclusion time 45 s). The HCD collision energy was set to 27% of the normalized collision
energy. Mass accuracy is checked before the start of samples analysis.
Mass spectrometry data analysis
Q Exactive Plus Mass Spectrometer. RAW files were analyzed, and peptides and proteins quantified
using MaxQuant (Cox and Mann, 2008), using the built-in search engine Andromeda (Cox et al.,
2011). All settings were set as default, except for the minimal peptide length of 5, and Andromeda
search engine was configured for the UniProt Homo sapiens protein database (release date:
2018_09). Peptide and protein ratios only quantified in at least two out of the three replicates were
considered, and the p-values were determined by Student’s t test and corrected for multiple testing
using the Benjamini–Hochberg procedure (Benjamini and Hochberg, 1995).
Plasmid constructs
For single-molecule fluorescence microscopy, monomeric non-fluorescent (Y67F) variant of eGFP
was N-terminally fused to GP130. This tag (mXFPm) was engineered to specifically bind anti-GFP
nanobody ‘minimizer’ (aGFP-miNB). This construct was inserted into a modified version of pSems-26
m (Covalys) using a signal peptide of Igk. The ORF was linked to a neomycin resistance cassette via
an IRES site. A mXFPe-IL-27Ra construct was designed likewise but is recognized by aGFP nano-
body ‘enhancer’ (mXFPe). The chimeric construct mXFP-IL-27Ra (ECD and TMD)-GP130(ICD) was a
fusion construct of IL-27Ra (aa 33–540) and GP130 (aa 645–918).
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Cell lines and media
RPE1 cells were grown in DMEM/F12 containing 10% v/v FBS, penicillin-streptomycin, and L-gluta-
mine (2 mM). RPE1 cells were stably transfected by mXFPe-IL-27Ra ( = ‘RPE1 IL-27Ra”), mutants
and the chimeric construct by PEI method according to standard protocols. Using G418 selection
(0.6 mg/ml) individual clones were selected, proliferated and characterized. RPE1 cells previously
knocked out for endogenous GP130 (Martinez-Fabregas et al., 2019) were stably transfected as
above with mXFPm-GP130 ( = ‘RPE1 10x[GP130]”).
Flow cytometry staining and antibodies
For measuring dose-response curves of STAT1/3 phosphorylation (either Th-1 cells or RPE1 clones),
96-well plated were prepared with 50 ml of cell suspensions at 2  106 cells/ml/well for Th-1 and 2 
105 cells/ml/well for RPE1. The latter were detached using Accutase (Sigma). Cells were stimulated
with a set of different concentrations to obtain dose-response curves. To this end, cells were stimu-
lated for 15 min at 37˚C with the respective cytokines followed by PFA fixation (2%) for 15 min at RT.
For kinetic experiments, cell suspensions were stimulated with a defined, saturating concentration
of cytokines (10 nM IL-27, 20 nM HypIL-6, 100 nM wt-IL-6) in a reverse order so that all cell suspen-
sions were PFA-fixed (2%) simultaneously. For pSTAT1/3 kinetic experiments at JAK inhibition, Tofa-
citinib (2 mM, Stratech, #S2789-SEL) was added after 15 min of stimulation and cells were PFA-fixed
in correct order.
After fixation (15 min at RT), cells were spun down at 300 g for 6 min at 4˚C. Cell pellets were
resuspended and permeabilized in ice-cold methanol and kept for 30 min on ice. After permeabiliza-
tion cells were fluorescently barcoded according to Krutzik and Nolan, 2006. In brief: using two
NHS-dyes (PacificBlue, #10163, DyLight800, #46421, Thermo Scientific), individual wells were stained
with a combination of different concentrations of these dyes. After barcoding, cells are pooled and
stained with anti-pSTAT1Alexa647 (Cell Signaling Technologies, #8009) and anti-pSTAT3Alexa488 (Biole-
gend, #651006) at a 1:100 dilution in PBS + 0.5% BSA for 1 hr at RT. T-cells were also stained with
anti-CD8AlexaFlour700 (1:120, Biolegend, #300920), anti-CD4PE (1:120, Biolegend, #357404), anti-
CD3BrilliantViolet510 (1:100, Biolegend, #300448). Cells were analzyed at the flow cytometer (Beckman
Coulter, Cytoflex S) and individual cell populations were identified by their barcoding pattern (supp.
Fig 1b). Mean fluorescence intensity (MFI) of pSTAT1647and pSTAT3488 was measured for all individ-
ual cell populations.
For measuring total STAT levels, methanol-permeabilized cells were stained with anti-STAT1A-
lexa647 (1:70, Biolegend, #558560) or anti-STAT3APC (1:50, Biolegend, #560392). Total IRF1 levels
methanol-permeabilized cells were stained with anti-IRF1Alexa647 (1:50, Biolegend, #14105). For mea-
suring cell surface levels of GP130, cells were detached with Accutase (Sigma) and stained with anti-
GP130APC (1:100, Biolegend, #362006) for 1 hr on ice. For measuring cell surface levels of mXFPe-IL-
27Ra variants, cells were detached with Accutase (Sigma) and stained with aGFP-enNBDy647 (10 nM)
for 30 min on ice.
RNA transcriptome sequencing
Human Th-1 cells from three donors each (StemCell Technologies) were cultivated and stimulated as
described in above. Cells were washed in Hank’s balanced salt solution (HBSS, Gibco) and snap fro-
zen for storage. RNA was isolated using the RNeasy Kit (Quiagen) according to manufacturer’s pro-
tocol. All RNA 260/280 ratios were above 1.9. Of each sample, 1 mg of RNA was used.
Transcriptomic analysis was done by Novogene as follows. Sequencing libraries were generated
using NEBNext UltraTM RNALibrary Prep Kit for Illumina (NEB, USA) following manufacturer’s rec-
ommendations and index codes were added to attribute sequences to each sample. Briefly, mRNA
was purified from total RNA using poly-T oligo-attached magnetic beads. Fragmentation was carried
out using divalent cations under elevated temperature in NEBNext First StrandSynthesis Reaction
Buffer (5X). First strand cDNA was synthesized using random hexamer primer and M-MuLV Reverse
Transcriptase (RNase H-). Second strand cDNA synthesis was subsequently performed using DNA
Polymerase I and RNase H. Remaining overhangs were converted into blunt ends via exonuclease/
polymerase activities. After adenylation of 3’ ends of DNA fragments, NEBNext Adaptor with hairpin
loop structure were ligated to prepare for hybridization. In order to select cDNA fragments of pref-
erentially 150 ~ 200 bp in length, the library fragments were purified with AMPure XP system
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(Beckman Coulter, Beverly, USA). Then 3 ml USER Enzyme (NEB, USA) was used with size-selected,
adaptor-ligated cDNA at 37˚C for 15 min followed by 5 min at 95˚C before PCR. Then PCR was per-
formed with Phusion High-Fidelity DNA polymerase, Universal PCR primers and Index (X) Primer. At
last, PCR products were purified (AMPure XP system) and library quality was assessed on the Agilent
Bioanalyzer 2100 system.
RNA sequencing data analysis
Primary data analysis for quality control, mapping to reference genome and quantification was con-
ducted by Novogene as outlined below.
Quality control: Raw data (raw reads) of FASTQ format were firstly processed through in-house
scripts. In this step, clean data (clean reads) were obtained by removing reads containing adapter
and poly-N sequences and reads with low quality from raw data. At the same time, Q20, Q30 and
GC content of the clean data were calculated. All the downstream analyses were based on the clean
data with high quality.
Mapping to reference genome: Reference genome and gene model annotation files were down-
loaded from genome website browser (NCBI/UCSC/Ensembl) directly. Paired-end clean reads were
mapped to the reference genome using HISAT2 software. HISAT2 uses a large set of small GFM
indexes that collectively cover the whole genome. These small indexes (called local indexes), com-
bined with several alignment strategies, enable rapid and accurate alignment of sequencing reads.
Quantification: HTSeq was used to count the read numbers mapped of each gene, including
known and novel genes. And then RPKM of each gene was calculated based on the length of the
gene and reads count mapped to this gene. RPKM, (Reads Per Kilobase of exon model per Million
mapped reads), considers the effect of sequencing depth and gene length for the reads count at the
same time and is currently the most commonly used method for estimating gene expression levels.
For each identified gene, the fold change was calculated by the ratio of cytokine stimulated/unsti-
mulated expression levels within each donor and an unpaired, two-tailed t test was applied to calcu-
late p values. Genes were considered to be significantly altered if: p value  0.05, and log2 fold
change +1 or  1. Genes with an RPKM of less than one in two or more donors were excluded
from analysis so as to remove genes with abundance near detection limit. Genes without annotated
function were also removed. Functional annotation of genes (KEGG pathways, GO terms) was done
using DAVID Bioinformatics Resource functional annotation tool (Huang et al., 2009a; Huang et al.,
2009b). Clustered heatmap was generated using R Studio Pheatmap package.
siRNA-mediated knockdown of IRF1 in RPE1 cells
A set of four IRF1-siRNAs were purchased from Dharmacon and tested individually to determine lev-
els of knockdown achieved. The siRNA providing the highest level of IRF1. knockdown (Horizon, LQ-
011704-00-0005, siRNA #2: UGAACUCCCUGCCAGAUAU) were subsequently used in all the experi-
ments. RPE1 IL-27Ra cells were plated in six-well dishes (0.4  106 cells per well) and transfected
the next day with IRF1-siRNA or control-GAPDH siRNA (Horizon, D-001830-10-05) (Dharmacon)
using DharmaFect one transfection reagent (Dharmacon) following the manufacturer’s instructions
for 24 hr. At different timepoints of IL-27 (2 nM) or HypIL-6 (10 nM) stimulation, samples were col-
lected from each one six-well. Cells were trypsinized and each sample was spun down and pellets
snap-frozen in liquid nitrogen for subsequent RNA isolation (90%) or PFA-fixed for total IRF1 staining
(10%) by flow cytometry.
Real-time quantitative PCR
Cells were subject to RNA isolation using the Qiagen RNeasy kit. RNA (100 ng) was reverse tran-
scribed to complementary DNA (cDNA) using an iScript cDNA synthesis kit (BioRad, #1708890),
which was used as template for quantitative PCR. PowerTrack SYBR Green Master Mix (Takara,
#A46109) was used for the reaction with the following primers:
Target For Rev Size
b-actin CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 250 bp
Continued on next page
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Continued
Target For Rev Size
STAT1 CTAGTGGAGTGGAAGCGGAG CACCACAAACGAGCTCTGAA 252 bp
GBP5 TCCTCGGATTATTGCTCGGC CCTTTGCGCTTCAGCCTTTT 309 bp
OAS1 GAAGGCAGCTCACGAAACC AGGCCTCAGCCTCTTGTG 114 bp
SOCS3 GTCCCCCCAGAAGAGCCTATTA TTGACGGTCTTCCGACAGAGAT 118
b-actin was used as housekeeping gene for normalization. Each siRNA knockdown experiment
was performed in four replicates with each sample for qPCR being done in two technical replicates.
Mathematical models
We developed two new mathematical models, making use of ordinary differential equations (ODEs),
for the initial steps of cytokine-receptor binding, dimer formation and signal activation by HypIL-6
and IL-27, respectively; namely, a set of ODEs for the HypIL-6 system and a separate one for the IL-
27 system (see Supplementary material 1 for the set of ODEs describing each model). These ODEs
describe the rate of change of the concentration for each molecular species considered in the recep-
tor-ligand systems (HypIL-6 and IL-27) over time. By solving these ODEs, a time-course for the con-
centration of total (free and bound) phosphorylated STAT1 and STAT3 can be obtained and
compared to the experimental data (Supp. Fig. 5c and 5d). The HypIL-6 and IL-27 mathematical
models differ due to the reactions involved in the formation of the signaling dimer for each cytokine.
Under stimulation with HypIL-6, two HypIL-6 bound GP130 monomers are required to form the
homodimer (Supp. Fig. 4b), Figure 2—figure supplement 1. Schematic model of involved reac-
tions and parameters for IL-27 and HypIL-6 receptor activation. whereas under IL-27 stimulation,
we assume that IL-27 binds to the IL-27Ra chain and not to GP130 (Supp. Fig. 4c) and hence the het-
erodimer is comprised of an IL-27 molecule bound to an IL-27Ra monomer and one GP130 chain. In
the mathematical models, we assume that upon formation of the dimers (homo- or heterodimer),
these receptor chains become immediately phosphorylated. The models do not consider JAK mole-
cules explicitly. We are assuming that these molecules are constitutively bound to their correspond-
ing receptor chains and that they phosphorylate immediately upon receptor phosphorylation (dimer
formation). After the formation of the dimer, which we denote by D6 or D27, formed by HypIL-6 or
IL-27 respectively, the biochemical reactions included in each mathematical model are similar, and
are summarized as follows. Table 2 provides a description of the rates for each reaction considered
in each (and both) mathematical model(s). In what follows we assume mass action kinetics for all the
reactions. A free cytoplasmic unphosphorylated STAT1 or STAT3 molecule can bind to either recep-
tor chain in the dimer, provided that the intracellular tyrosine residue of the receptor in the dimer is
free (Supp. Fig. 4d and 4e). The STAT1 or STAT3 molecule can subsequently dissociate from the
receptor chain in the dimer or can become phosphorylated (with rate q) whilst bound to the dimer.
We have assumed that the rate of STAT1 or STAT3 phosphorylation when bound does not depend
on the STAT type (1 or 3) or on the receptor chain (Supp. Fig. 4d and 4e). Phosphorylated STAT1
(pSTAT1) and STAT3 (pSTAT3) molecules can dissociate from the dimer. Once free in the cytoplasm,
they can then dephosphorylate (Supp. Fig. 4h). We have assumed that this rate of STAT dephos-
phorylation only depends on the concentration of the respective pSTAT type. We note that no allo-
stery has been considered in the models and hence, phosphorylated and unphosphorylated STAT
molecules dissociate from the receptor with the same rate (Supp. Fig. 4d and 4e). Finally, any molec-
ular species containing receptor molecules can be lost from the system, due to internalization or
degradation processes, via one of two hypothesized mechanisms (Supp. Fig. 4f and 4g):
. hypothesis 1 (H1): receptors (free or bound, phosphorylated or unphosphorylated) are internal-
ized/degraded with a rate proportional to the concentration of the species in which they are
contained, or
. hypothesis 2 (H2): receptors (free or bound, phosphorylated or unphosphorylated) are internal-
ized/degraded with a rate proportional to the product of the concentration of the species in
which they are contained and the sum of the concentrations of free cytoplasmic phosphory-
lated STAT1 and STAT3.
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We note that hypothesis 1 assumes that receptor molecules (free or bound, phosphorylated or
unphosphorylated) are being internalized/degraded as part of the natural cellular trafficking cycle.
Hypothesis 2 is consistent with a potential feedback mechanism, whereby the free cytoplasmic
pSTAT molecules would migrate to the nucleus and increase the translation of negative feedback
proteins, such as SOCS3, which down-regulate cytokine signaling. Thus, the internalization/degrada-
tion rate of receptor molecules (free or bound, phosphorylated or unphosphorylated) under hypoth-
esis 2 increases with the total amount of free cytoplasmic phosphorylated STAT1 and STAT3, to
account for this negative feedback on surface receptor expression. A depiction of the reactions in
both the HypIL-6 and IL-27 mathematical models and under each hypothesis is given in Supp. Fig. 4
where (b), (d), (f) and (h) describe the HypIL-6 model and (c), (e), (g) and (h) describe the IL-27 model.
In this figure, i 2 1; 3f g so that the reactions shown can involve STAT1 or STAT3. Each reaction arrow
has been shown with its rate (above or below the arrow). We note that we assume mass action kinet-
ics for each reaction. The notation for the rate constants and initial molecular concentrations in the
models, along with their descriptions and units, are given in Table 2.
The HypIL-6 mathematical model was formulated based on biochemical reactions involving the
following species:
. L6 ¼ HypIL-6,
. R1 ¼ GP130,
. C1 ¼ GP130 - HypIL-6 monomer,
. D6 ¼ phosphorylated GP130 - HypIL-6 - HypIL-6 - GP130 homodimer,
. S1 ¼ unbound cytoplasmic unphosphorylated STAT1,
. S3 ¼ unbound cytoplasmic unphosphorylated STAT3,
. D6  S1 ¼ dimer bound to STAT1,
. D6  S3 ¼ dimer bound to STAT3,
. D6  pS1 ¼ dimer bound to pSTAT1,
. D6  pS3 ¼ dimer bound to pSTAT3,
. S1  D6  S1 ¼ dimer bound to two molecules of STAT1,
. pS1  D6  S1 ¼ dimer bound to two molecules of STAT1, one of which is phosphorylated,
. pS1  D6  pS1 ¼ dimer bound to two molecules of pSTAT1,
. S3  D6  S3 ¼ dimer bound to two molecules of STAT3,
. pS3  D6  S3 ¼ dimer bound to two molecules of STAT3, one of which is phosphorylated,
. pS3  D6  pS3 ¼ dimer bound to two molecules of pSTAT3,
Table 2. Parameter mathematical notation, description, and units, where i 2 1; 3f g so that STAT i




















2;27 Rate of dimer dissociation s
 1
kþia Rate of STATi binding to GP130 nM
 1s 1
kþib Rate of STATi binding to IL-27Ra nM
 1s 1
k ia Rate of STATi dissociating GP130 s
 1
k ib Rate of STATi dissociating IL-27Ra s
 1
q Rate of STATi phosphorylation on a dimer s 1
di Rate of pSTATi dephosphorylation s
 1
b6;b27 Rate of receptor internalization/degradation under hypothesis 1 s
 1
g6; g27 Rate of receptor internalization/degradation under hypothesis 2 nM
 1s 1
R1 0ð Þ½  Initial concentration of GP130 nM
R2 0ð Þ½  Initial concentration of IL-27Ra nM
Si 0ð Þ½  Initial concentration of STATi nM
Wilmes, Jeffrey, et al. eLife 2021;10:e66014. DOI: https://doi.org/10.7554/eLife.66014 30 of 44
Research article Computational and Systems Biology Immunology and Inflammation
. S1  D6  S3 ¼ dimer bound to one molecule of STAT1 and one of STAT3,
. pS1  D6  S3 ¼ dimer bound to one molecule of pSTAT1 and one of STAT3,
. S1  D6  pS3 ¼ dimer bound to one molecule of STAT1 and one of pSTAT3,
. pS1  D6  pS3 ¼ dimer bound to one molecule of pSTAT1 and one of pSTAT3,
. pS1 ¼ unbound cytoplasmic phosphorylated STAT1,
. pS3 ¼ unbound cytoplasmic phosphorylated STAT3.
The initial reactions in the HypIL-6 signaling pathway can then be described by the ODEs (1) –
(22) in the supplementary text, under the law of mass action, where the terms involving the parame-
ter b6 apply only to the model under hypothesis 1 and the terms involving the parameter g6 apply
only to the model under hypothesis 2. Square brackets around a species denote the concentration
of this species with unit nM, and “.” implies a reaction bond between two molecules/species. The
ODEs are valid for any time t, with t  0, but time has been omitted in the species concentration for
ease of notation. We note here that, for example R1½  ¼ R1½  tð Þ for all t  0.
Similarly, and with some species in common with the HypIL-6 model, the IL-27 model has been
formulated based on biochemical reactions involving the following species:
. L27 ¼ IL-27,
. R1 ¼ GP130,
. R2 ¼ IL-27Ra,
. C2 ¼ IL-27Ra - IL-27 monomer,
. D27 ¼ phosphorylated IL-27Ra - IL-27 - GP130 heterodimer,
. S1 ¼ unbound cytoplasmic unphosphorylated STAT1,
. S3 ¼ unbound cytoplasmic unphosphorylated STAT3,
. S1  D27 ¼ dimer bound to STAT1 via R1,
. S3  D27 ¼ dimer bound to STAT3 via R1,
. pS1  D27 ¼ dimer bound to pSTAT1 via R1,
. pS3  D27 ¼ dimer bound to pSTAT3 via R1,
. D27  S1 ¼ dimer bound to STAT1 via R2,
. D27  S3 ¼ dimer bound to STAT3 via R2,
. D27  pS1 ¼ dimer bound to pSTAT1 via R2,
. D27  pS3 ¼ dimer bound to pSTAT3 via R2,
. S1  D27  S1 ¼ dimer bound to two molecules of STAT1,
. pS1  D27  S1 ¼ dimer bound to two molecules of STAT1, phosphorylated on R1,
. S1  D27  pS1 ¼ dimer bound to two molecules of STAT1, phosphorylated on R2,
. pS1  D27  pS1 ¼ dimer bound to two molecules of pSTAT1,
. S3  D27  S3 ¼ dimer bound to two molecules of STAT3,
. pS3  D27  S3 ¼ dimer bound to two molecules of STAT3, phosphorylated on R1,
. S3  D27  pS3 ¼ dimer bound to two molecules of STAT3, phosphorylated on R2,
. pS3  D27  pS3 ¼ dimer bound to two molecules of pSTAT3,
. S1  D27  S3 ¼ dimer bound to STAT1 via R1 and STAT3 via R2,
. S3  D27  S1 ¼ dimer bound to STAT1 via R2 and STAT3 via R1,
. pS1  D27  S3 ¼ dimer bound to pSTAT1 via R1 and STAT3 via R2,
. S3  D27  pS1 ¼ dimer bound to pSTAT1 via R2 and STAT3 via R1,
. S1  D27  pS3 ¼ dimer bound to STAT1 via R1 and pSTAT3 via R2,
. pS3  D27  S1 ¼ dimer bound to STAT1 via R2 and pSTAT3 via R1,
. pS1  D27  pS3 ¼ dimer bound pSTAT1 via R1 and pSTAT3 via R2,
. pS3  D27  pS1 ¼ dimer bound pSTAT3 via R1 and pSTAT1 via R1,
. pS1 ¼ unbound cytoplasmic phosphorylated STAT1,
. pS3 ¼ unbound cytoplasmic phosphorylated STAT3.
Again, under the law of mass action, the initial reactions in the IL-27 signaling pathway can be
described by the ODEs (23) – (55) in the supplementary text. Similarly, to the HypIL-6 model, the
terms in the supplementary Equations (23) - (55) involving the parameter b27 apply only to the model
under hypothesis 1 and the terms involving the parameter g27 apply only to the model under hypoth-
esis 2.
We now describe how we have made use of the experimental data (Supp. Fig. 5c and 5d) to
parameterize the mathematical models described above. Since the experimental outputs are levels
of pSTAT1 and pSTAT3 as a function of time under HypIL-6 and IL-27 stimulation (Supp. Fig. 5c &
5d), we consider two model outputs of interest for the HypIL-6 and IL-27 mathematical models,
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which are proportional to the experimental data in Supp. Fig. 5c & 5d; namely, the sum of all molec-
ular species (variables) containing phosphorylated STAT1 (free or bound) ( pS1½ 
T;j, for j 2 6; 27f g) and
the sum of all species (variables) containing phosphorylated STAT3 (free or bound) ( pS3½ 
T;j,
for j 2 6; 27f g). The total concentrations of the two model outputs of interest at any time t are




tð Þ ¼ ½D6  pS1ðtÞþ ½pS1 D6  S1ðtÞþ 2½pS1 D6  pS1ðtÞþ ½pS1 D6  S3ðtÞ




tð Þ ¼ ½D6  pS3ðtÞþ ½pS3 D6  S3ðtÞþ 2½pS3 D6  pS3ðtÞþ ½pS3 D6  S1ðtÞ
þ½pS3 D6  pS1ðtÞþ ½pS3ðtÞ
; (2)
for the HypIL-6 model, and by
pS1½ 
T;27
tð Þ ¼ ½pS1 D27ðtÞþ ½D27  pS1ðtÞþ ½pS1 D27  pS1ðtÞþ ½S1 D27  pS1ðtÞ
þ2½pS1 D27  pS1ðtÞþ ½pS1 D27  S3ðtÞþ ½S3 D27  pS1ðtÞ




tð Þ ¼ ½pS3 D27ðtÞþ ½D27  pS3ðtÞþ ½pS3 D27  pS3ðtÞþ ½S3 D27  pS3ðtÞ
þ2½pS3 D27  pS3ðtÞþ ½pS3 D27  S1ðtÞþ ½S1 D27  pS3ðtÞ
þ½pS1 D6  pS3ðtÞþ ½pS3 D6  pS1ðtÞþ ½pS3ðtÞ;
(4)
for the IL-27 model.
Bayesian inference
Having developed two mathematical models to describe the experimental system of HypIL-6 and IL-
27 stimulation, it was then our objective to parameterize the rates of these models, making use of
approximate Bayesian Computation sequential Monte Carlo (ABC-SMC) and Bayesian model selec-
tion (selecting between hypothesis 1 and 2, as described in the previous section). In this way, we can
learn about which reactions and parameters in the models are regulating the differential signaling by
pSTAT1 observed when stimulating with HypIL-6 and IL-27.
Model (hypothesis) selection and parameter estimation are carried out together in the Bayesian
sequential Monte Carlo framework used. In the traditional ABC rejection algorithm (Sunnåker et al.,
2013), the parameters of a mathematical model are sampled from determined prior distributions
and the mathematical model is simulated with the sampled (from those prior distributions) parame-
ter values. If the model output is ’close’ to the experimental data, as defined by a quantitative mea-
sure of distance d, that is, if the distance between mathematical model output and experimental
data points is smaller than a fiducial threshold d, that is, d<d, then the parameters sampled for this
instance are accepted into a posterior distribution, otherwise they are rejected. This process is
repeated until a posterior of size N is obtained. For ODE models with a small number of parameters
and variables, this approach can work well. However, for larger, more complex models, such as the
models considered here, this approach can be very time consuming, since one must simulate the
model a large number of times in order to obtain a posterior sample of size N. This is due to the
high dimensionality of the parameter space. For example, in the case of the HypIL-6 model, there
are 16 parameters, and thus, a 16-dimensional parameter space. There is, therefore, likely to be
large areas of parameter space for which, when the parameters are sampled, the distance measure,
d, between the model and data is always greater than d, and hence this procedure is not an efficient
sampling strategy.
To this end, we chose to use a more accurate, iterative method, ABC-SMC. At the first iteration,
the algorithm works in the same way as the rejection algorithm (described above), where “particles”
(parameter sets) are accepted if they result in a distance d<d1, where d1 is reasonably large; for
instance, if approximately 50% of all parameter sets sampled lead to a distance d<d1. At each suc-
cessive iteration, the parameters are sampled not from the prior distributions, but from the posterior
distributions which have been obtained from the previous iteration, with weights that depend on
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both the prior and the previous iteration distributions. The parameters are then perturbed slightly
using a perturbation kernel (for more details see Toni et al., 2009) and the model is simulated as
above. A particle at iteration i is accepted if it results in a distance measure d<di, where the delta
values form a decreasing sequence, d1>d2>d3>   >dM , for M iterations. In this way, at each iteration
the parameters are sampled from a reduced parameter space region, and hence this approach leads
to a faster, more efficient, convergence to the posterior distributions.
A model (hypothesis) selection can be performed making use of the iterative method described
above (see Toni et al., 2009). We consider a given model (hypothesis) and its parameters are sam-
pled from either the prior (iteration 1) or the previous iterations posterior distributions (iteration
i such that 1<i<M; in which case the parameters are also perturbed), and again the particle is
accepted if the distance between mathematical model output and experimental data points is such
that d<di for iteration i. This procedure continues until we obtain a posterior distribution of size
N for each mathematical model (hypothesis) considered. The mathematical models are initially given
equal weight; that is, they are considered to be equally likely. However, as the iterations of the infer-
ence algorithm proceed, if one mathematical model (hypothesis) results in parameter values that
better explain the experimental data, this model (hypothesis) will have a greater number of parame-
ter sets accepted per iteration, in the limit i ! M. Thus, model selection between two mathematical
models (hypotheses) can be determined by the computation of the relative probability for each
model (hypothesis) k at iteration i, denoted by Pki , and defined as follows:
Pki ¼
numberof acceptedparticlesat iteration i frommodel hypothesisð Þk
N
;
for k 2 1;2f g: The limit limi!MP
k
i gives the probability P
k which yields the relative probability of math-
ematical model k in light of the experimental data.
The data sets we used to compare with the mathematical model outputs were the mean relative
fluorescence intensity of total phosphorylated STAT1 and total phosphorylated STAT3 for the cyto-
kine stimulation experiments with both RPE1 and Th-1 cells (Supp. Figure 5b and 5c). Given that the
data points have units of mean fluorescence intensity and the model output has dimensions of con-
centration (in nM units), we normalized the data sets to obtain dimensionless values, which in turn
can be compared with the normalized mathematical model outputs. To this end, and firstly, we con-
structed a linear model for the fluorescence intensity (background fluorescence) of antibodies of
phosphorylated STAT1 and STAT3 in unstimulated cells. We then subtracted the value of this linear
model at each time point from the corresponding fluorescence intensity in HypIL-6 and IL-27-stimu-
lated cells, for each repeat of the experiment and cell type. Let us denote by f the experimental fluo-
rescence intensity, f r; i; tp; j; dð Þ corresponds to the fluorescence intensity for the r th repeat,
r 2 R ¼ 1; 2; 3; 4f g with antibody for STATi, i 2 I ¼ 1; 3f g at time point tp;
tp2 TP¼ 0min;5min;15min;30min;60min;90min;120min;180minf g
under stimulation by cytokine IL-j (HypIL-j when j¼ 6), with j 2 J ¼ 6;27f g and in cell
type d 2D¼ RPE1;Th  1f g: Each data point data r; i; tp; j;dð Þ; to be used in the Bayesian inference
and Bayesian model selection was then obtained from f r; i; tp; j;dð Þ with the following normalization,
data r; i; tp; j;dð Þ ¼
f r; i; tp; j;dð Þ
f r; i; tp¼ 30min; j¼ 27;dð Þ
: (5)
That is, our normalization has been chosen to be the time point 30 minutes with IL-27 stimulation.
To compare the mathematical model output, denoted by sim i; tp; j;dð Þ; with the normalized experi-
mental data, the mathematical output was normalized in the same way as the data, that is,










tp;dð Þ denotes the total, T, concentration of phosphorylated STATi at time tp (see Equa-
tions 1–4) when considering cell type d and cytokine stimulation j2 J ¼ 6;27f g. The data points for
IL-27 stimulation at time 30 mins were chosen as normalization in Equation (5), since they corre-
spond to the maximal experimental value, and thus the data, when normalized in this way, was
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transformed to a scale in the interval 0;1½ . Mathematical model outputs were normalized in the
same way, and therefore model outputs for IL-27 will naturally go through the value 1 at time
30 mins. This choice of normalization has not influenced the results of our study. To this end, we
have repeated our analysis with a different normalization time point of
f r; i; tp¼ 15min; j¼ 27;dð Þ (results not shown here). In particular, we found that the posterior distribu-
tions and the result of the model (hypothesis) selection were rather similar for each choice of
normalization.
Once data sets and mathematical outputs have been normalized and can be compared, there is a
need to quantify how close (or not) they are. To this end, we make use of a quantitative measure,











½simði; tp; j;dÞ dataði; tp; j;dÞ
2; (7)
d 2D¼ RPE1;Th  1f g, with data i; tp; j;dð Þ defined as the mean of the four experimental repeats. The
mean is given by






data r; i; tp; j;dð Þ: (8)
With a choice of measure, we can now carry out both Bayesian (mathematical) model selection
and parameter inference. Before we do so, our prior beliefs of the parameters need to be consid-
ered and defined. Each of the parameters (reaction rates in the mathematical models) and initial con-
centrations for the molecules in the model were sampled from a prior distribution, where the
distribution was informed by independent experiments or published values, when possible. The
choice of prior distributions is given in Table 3.
We now provide additional details of the model selection and parameter estimation carried out
with the normalized experimental data and mathematical models. We have experimental data for
two different cell types (RPE1 and Th-1). There are a number of parameters in the HypIL-6 and IL-27
mathematical models which we have assumed to be independent of the cell type. The only parame-
ters which we would expect to differ between cell types are the initial concentrations of the mole-
cules ([R1 (0)], [R2 (0)], [S1 (0)], [S3 (0)]), the rate of STAT phosphorylation (q), the rates of pSTAT
dephosphorylation (d1, d3) and the rates of internalization/degradation of the receptor molecules
(b6, b27, g6, g27). Therefore, the aforementioned parameters have been estimated for each cell type,
separately, and the rest of the parameters have been estimated with one cell type. We have chosen
to make use of the RPE1 data to estimate these shared parameters. In particular, we ran the analysis
in two stages (all our numerical codes were written in Python), in order to reduce the number of
parameters to be estimated in a given ABC-SMC analysis. We first made use of the RPE1 data and
secondly, the Th-1 data. We ran the model (hypothesis) selection algorithm with the RPE1 data, for a
sample of size N ¼ 104 and M ¼ 15 iterations, with the following sequence of delta
values 100; 10; 5; 3; 2:5; 2:25; 2; 1:75; 1:5; 1:25; 1:1; 1; 0:9; 0:8; 0:7f g.
A uniform perturbation kernel (Filippi et al., 2013) was used to perturb the parameters sampled
at each iteration 1<i  M. The result of the model selection clearly indicated that hypothesis 1 could
explain the experimental data best.
When carrying out model (hypothesis) selection, and during the latter iterations, there were still
some parameter sets accepted for hypothesis 2. Therefore, we ran the ABC-SMC parameter estima-
tion algorithm for the RPE1 data only for hypothesis 1, in order to generate a complete posterior
distribution of size N ¼ 104. In the second stage of the inference, we then considered the Th-1 data
and ran the ABC-SMC parameter estimation algorithm to infer Th-1 specific parameters (only for
hypothesis 1). Those parameters that were assumed to be independent of cell type were sampled
from the posterior distributions obtained during the previous RPE1 ABC-SMC inference. The same
sample size, number of iterations, vector of delta values and perturbation kernel were used in the
Th-1 and RPE1 analysis. We finally note that, although we used the experimental data sets in the
order RPE1 followed by Th-1 here, the ordering of the cell type does not have a significant effect on
the results (not shown here). Namely, our model selection results and those of the parameter infer-
ence and posterior distributions are similar to those presented here, when we reverse the order.
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Mathematical model validation
Once we have carried out model selection and parameter inference as described in the previous sec-
tion, we want to explore the potential of the mathematical models of cytokine early signaling to
reproduce other independent experiments. We note that we make use of the posterior parameter
distributions obtained from the RPE1 data ABC-SMC. Our first interest was to reproduce the dose
response curve seen in Supp. Fig. 2a. To this end, we run both models using the 104 accepted
parameters sets from the ABC-SMC for 18 different values of cytokine concentration, within the
range [10-4-102] log nM. The results of this analysis are seen in Supp. Fig. 13b. Our second interest
was to describe the IL-27Ra-GP130 chimera experiments (Figure 3c). This required us to modify the
mathematical model as follows: we considered the ODEs of the IL-27 mathematical model involved
in the formation of the dimer, Equations (23) – (26) (Supplementary information 1), and the ODEs of
the HypIL-6 mathematical model post-dimer formation, Equations (5) – (22) (Supplementary informa-
tion 1), in which D6 was replaced by D27. The ODE of the IL-27 induced dimer in the chimera model




2;27 C2½  R1½   r
 
2;27 D27½    2k
þ
1a D27½  S1½ þ k
 
1a S1_D27½  þ ½pS1_D27ð Þ
 2kþ
3a D27½  S3½ þ k
 
3a S3_D27½ þ ½pS3_D27ð Þ b27½D27:
(9)
We simulated both the original mathematical model of IL-27 and the chimera model using the
accepted parameter sets from the ABC-SMC. The results can be seen in Supp. Fig. 3a.
Finally, the mathematical model was used to describe one of the mutant varieties of the IL-27Ra
chain, Y613F. We sought to reproduce the results of Figure 3b making use of the mathematical
model of IL-27 signaling. Since the Y613F mutation decreases the affinity of STAT1 to IL-27Ra, we




Table 3. Prior distribution assigned to each parameter and initial molecular concentration.
*These distributions are centered around measurements obtained from cell surface receptor quantifi-
cation experiments. **These distributions were derived based on Kd values obtained from the litera-
ture (Wiederkehr-Adam et al., 2003). ***These distributions are based on values derived from
experimental data in which the cells were treated with Tofacitinib. † These distributions were based
on values derived from experimental data in which the cells were treated with cycloheximide. ‡These
distributions were based on computations involving approximate cell sizes and average numbers of
molecules per cell.
Parameter Prior distribution Reference
rþ
1;6 10
r for r ~Nð 3; 1:5Þ *
r 
1;6 10
r for r ~Nð 3:9; 1:96Þ *
rþ
1;27 10
r for r ~Nð 2:34; 1:17Þ *
r 
1;27 10
r for r ~Nð 2:82; 1:41Þ *
rþ
2;j for j2{6,27} 10
r for r ~Unif ð 2; 3Þ Kozer et al., 2013
r 
2;j for j2{6,27} 10
r for r ~Unif ð 3; 1Þ Kozer et al., 2013
kþia ,k
þ
ib for i2{1,3} 10
r for r ~Unif ð 7; 1Þ **
k ia ,k
 
ib for i2{1,3} 10
r for r ~Unif ð 2; 1Þ **
q 10r for r ~Unif ð 3; 2Þ Assumed
di for i2{1,3} 10
r for r ~Unif ð 5; 2Þ ***
bj for j2{6,27} 10
r for r ~Unif ð 5; 1Þ †
gj for j2{6,27} 10
r for r ~Unif ð 5; 1Þ †
R1 0ð Þ½  N 12:7; 6:35ð Þ ‡
R2 0ð Þ½  N 33:8; 16:9ð Þ ‡
S1 0ð Þ½  N 300; 100ð Þ Itzhak et al., 2016
S3 0ð Þ½  N 400; 100ð Þ Itzhak et al., 2016
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at values which lead to a high affinity (of the order of mM values). The specific values chosen were
kþ
1b ¼ 10
 5 nM 1s 1 and k 
1b ¼ 10
1 s 1, which yield an affinity of 102mM. The rate k 
1b, was chosen as
approximately the median of the ABC-SMC posterior distribution for this parameter, and the rate kþ
1b
was then significantly decreased in order to increase the affinity. We simulated the mathematical
model of IL-27 signaling using the 104 accepted ABC-SMC parameter sets, but where the rates kþ
1b
and k 
1b, were fixed as described above. The pointwise medians and 95% credible intervals of these
simulations are plotted in Supp. Fig. 13c, as well as the simulations for the WT IL-27Ra chain, without
altering any of the parameter values from the posterior distributions. Altering the binding affinity of
STAT1 to IL-27Ra in this way in the mathematical model allows us to generate results which qualita-
tively and quantitatively reproduce the experimental observations for the Y613F mutant from
Figure 3b.
Live-cell dual-color single-molecule imaging studies
Single-molecule imaging experiments were carried out by total internal reflection fluorescence (TIRF)
microscopy with an inverted microscope (Olympus IX71) equipped with a triple-line total internal
reflection (TIR) illumination condenser (Olympus) and a back-illuminated electron multiplied (EM)
CCD camera (iXon DU897D, 512  512 pixel, Andor Technology) as recently described
(Wilmes et al., 2015; Wilmes et al., 2020; Moraga et al., 2015b). A 150 magnification objective
with a numerical aperture of 1.45 (UAPO 150 3/1.45 TIRFM, Olympus) was used for TIR illumination.
All experiments were carried out at room temperature in medium without phenol red supplemented
with an oxygen scavenger and a redox-active photoprotectant to minimize photobleaching
(Vogelsang et al., 2008). For Heterodimerization experiments of IL-27Ra and GP130 cell surface
labeling of RPE1 GP130 KO, co-transfected with mXFPe-IL-27Ra and mXFPm-GP130, was achieved
by adding aGFP-enNBRHO11 and aGFP-miNBDY647 to the medium at equal concentrations (5 nM)
and incubated for at least 5 min prior to stimulation with IL-27 (20 nM) or HypIL-6 (20 nM). For
homodimerization experiments with mXFPm-GP130, aGFP-miNBDY647 and aGFP-miNBRHO11
(Kirchhofer et al., 2010) were used for cell surface receptor labeling as described above. The nano-
bodies were kept in the bulk solution during the whole experiment in order to ensure high equilib-
rium binding to mXFP-GP130. For simultaneous dual-color acquisition, aGFP-NBRHO11 was excited
by a 561 nm diode-pumped solid-state laser at 0.95 mW (~32 W/cm2) and aGFP-NBDY647 by a 642
nm laser diode at 0.65 mW (~22 W/cm2). Fluorescence was detected using a spectral image splitter
(DualView, Optical Insight) with a 640 DCXR dichroic beam splitter (Chroma) in combination with the
bandpass filter 585/40 (Semrock) for detection of RHO11 and 690/70 (Chroma) for detection of
DY647 dividing each emission channel into 512  256 pixel. Image stacks of 150 frames were
recorded at 32 ms/frame.
Single-molecule localization and single-molecule tracking were carried out using the multiple-tar-
get tracing (MTT) algorithm (Sergé et al., 2008) as described previously (You et al., 2016). Step-
length histograms were obtained from single-molecule trajectories and fitted by two fraction mixture
model of Brownian diffusion. Average diffusion constants were determined from the slope (2–10
steps) of the mean square displacement versus time lapse diagrams. Immobile molecules were iden-
tified by the density-based spatial clustering of applications with noise (DBSCAN) algorithm as
described recently (Röder et al., 2014). For comparing diffusion properties and for co-tracking anal-
ysis, immobile particles were excluded from the data set. Prior to co-localization analysis, imaging
channels were aligned with sub-pixel precision by using a spatial transformation. To this end, a trans-
formation matrix was calculated based on a calibration measurement with multicolor fluorescent
beads (TetraSpeck microspheres 0.1 mm, Invitrogen) visible in both spectral channels (cp2tform of
type ‘affine’, The MathWorks MATLAB 2009a).
Individual molecules detected in the both spectral channels were regarded as co-localized, if a
particle was detected in both channels of a single frame within a distance threshold of 100 nm
radius. For single-molecule co-tracking analysis, the MTT algorithm was applied to this dataset of
co-localized molecules to reconstruct co-locomotion trajectories (co-trajectories) from the identified
population of co-localizations. For the co-tracking analysis, only trajectories with a minimum of 10
steps (~320 ms) were considered in order to robustly remove random receptor co-localizations
(Wilmes et al., 2020). For heterodimerization experiments of mXFPe-IL-27Ra and mXFPm-GP130,
the relative fraction of dimerized receptors was calculated from the number of co-trajectories
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relative to the number of IL-27Ra trajectories. GP130 was expressed in moderate excess (~1.5–2
fold), so that maximal receptor assembly was not limited by abundance of the low-affinity subunit
GP130.
For homodimerization experiments with GP130, the relative fraction of co-tracked molecules was
determined with respect to the absolute number of trajectories and corrected for GP130 stochasti-








 h i ; rel:co  locomotion¼
2AB
AþBð Þ
where A, B, AB, and AB* are the numbers of trajectories observed for Rho11, DY647, co-trajecto-
ries and corrected co-trajectories, respectively.
The two-dimensional equilibrium dissociation constants (K2DD ) were calculated according to the
law of mass action for a monomer-dimer equilibrium:
Heterodimerization (IL-27Ra + GP130):
K2DD ¼
½GP130  a½IL27Rað Þð Þ ½IL27Ra  a ½IL27Rað Þð Þ
a½IL27Rað Þ
or





þ IL27Ra½  a  1ð Þ
with:
a¼ fractionof IL27bound IL27RaincomplexwithGP130











GP130½   2 a GP130½ ð Þð Þ2
2 a GP130½ ð Þ
with:
a¼ fractionof GP130homodimersrelative to GP130½ =2
where [M] and [D] are the concentrations of the monomer and the dimer, respectively, and [M]0 is
the total receptor concentration.
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RNA-seq dataset was uploaded in the GSE database with accession number GSE164479.
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